

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014643 A2

- (51) International Patent Classification⁷: **C07K 14/54**
- (21) International Application Number:
PCT/EP2004/009165
- (22) International Filing Date: 29 July 2004 (29.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/490,525 29 July 2003 (29.07.2003) US
- (71) Applicant (for all designated States except US): **INSERM (Institut National de la Santé et de la Recherche Médicale)** [FR/FR]; 101, rue de Tolbiac, F-75654 Paris Cedex 13 (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PARIS, François, Emmanuel**. [FR/FR]; 20, Rue Auguste Brizeux, F-44000 Nantes (FR). **JACQUES, Yannick** [FR/FR]; 32 bis, rue Noire, F-44000 Nantes (FR). **CONTENT, Jean** [BE/BE]; Avenue Simone Rhode 5, B-1640 Saint Genese (BE). **WANG, Xiao-Ming** [BE/BE]; Boulevard du Souverain 356/bt21, B-1160 Bruxelles (BE). **HARMEGNIES, Dimitri** [BE/BE]; 6, rue des Eperonniers, B-1000 Bruxelles (BE). **GRÖTZINGER, Joachim** [DE/DE]; Steenrott 20, D-21242 Altwittenbek (DE).
- (74) Agent: **PARIS, Fabienne**; Cabinet Plasseraud, 65/67, rue de la Victoire, F-75440 Paris Cedex 09 (FR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IL-11 MUTEINS

(57) Abstract: The present invention relates to new IL-11 muteins of which site I hydrophobicity has been increased. These muteins act as IL-11 agonist or hyperagonist, and are notably useful as anti-thrombocytopenia agents, and as agents improving the resistance of an organism to the deleterious *in vivo* effects induced by radiation or chemotherapy during the treatment of cancer or for the preparation of patient to transplantation.



WO 2005/014643 A2

TITLE OF THE INVENTION : IL-11 muteins**BACKGROUND OF THE INVENTION :**

5

Human interleukin-11 (hIL-11) is a multi-potential cytokine that is involved in numerous biological activities such as hematopoiesis, osteoclastogenesis, neurogenesis and female fertility. It also displays anti-inflammatory properties. hIL-11 is clinically used to treat chemotherapy-induced thrombocytopenia.

10 Interleukin-11 was cloned from the primate stromal cell line PU-34 and was initially considered as a haematopoietic cytokine. It was later found that it also has effects on non-haematopoietic systems and that it acts on many different cell types and tissues. Numerous experiments on animal models and clinical trials with patients suffering from acute and chronic inflammatory diseases, including rheumatoid arthritis, inflammatory
15 bowel disease, inflammatory liver disease, mucositis and psoriasis have revealed that IL-11 is an anti-inflammatory and mucosal protective agent, which, by inhibiting nuclear translocation of nuclear factor- κ B (NF- κ B), can reduce the production of pro-inflammatory cytokines secreted by macrophages such as TNF- α , IL-1 β , IL-6 and IL-12. Its radio-protective and septic shock-protective activities have also been
20 demonstrated in other experiments. The clinical application of hIL-11 has been approved by the FDA for the treatment of chemotherapy-induced thrombocytopenia due to the ability of this cytokine to stimulate megakaryocytopoiesis and thrombopoiesis. Another potential therapeutic application of IL-11 in the treatment of mild hemophilia A or von Willebrand disease was recently evidenced by the fact that IL-11 is able to
25 increase von Willebrand factor and factor VIII production in a von Willebrand disease mouse model as well as in healthy mice.

Because of its broad spectrum of action, improved agonists as well as IL-11 antagonist would be of interest for numerous biological and clinical applications.

30

Some structure studies of IL-11 molecule have been conducted to elucidate the interactions involved in IL-11 activation and signalling.

The structure study of Czupryn *et al.* 1995 thus describes the production of 61 mutated forms of hIL-11 from *E. coli* as thioredoxin fusion proteins [Czupryn *et al.* (1995) Alanine-scanning mutagenesis of human interleukin-11: identification of regions important for biological activities. Ann. New York Acad. Sci. Jul 21 ; 762, 152-164].

5 Testing of these mutated forms in a murine T10 plasmacytoma proliferation assay led to the conclusion that mutations made several positions proximal to the hIL-11 C-terminus, such as a D186A mutation, caused substantial reduction in biological activity (the D186A mutation induced a 500-fold decrease in biological activity on the murine plasmacytoma cell line T10), and that a number of other mutations in this region

10 affected either protein folding or stability.

Tacke *et al.* 1999 have built a three-dimensional model of human IL-11 [Tacke *et al.* (1999) Definition of receptor binding sites on human interleukin-11 by molecular modelling-guided mutagenesis. Eur. J. Biochem. 265, 645-655]. Three receptor binding

15 sites within the IL-11 molecule have thus been defined (see site I, site II and site III on Figure 1B of Tacke *et al.* 1999).

In Tacke *et al.* 1999 study, ten surface-exposed amino acid have thus selected within sites I, II and III as candidate for single point mutagenesis assays (only one amino acid per molecule has been mutated). The single point mutations made consisted in replacing

20 a hydrophobic side chain by a charged group (aspartic acid), and a charged chain by an oppositely charged residue (lysine or glutamic acid) in order to introduce a substantial disturbance into the receptor binding sites. Nine of the ten single point mutants thus produced, including those four for which the single point mutation was on an amino acid belonging to site I (A84D mutant ; L85D mutant ; R190E mutant ; L194D mutant),

25 led to a substantially reduced affinity for the IL-11 receptor complex, and to a loss or a substantially reduced bioactivity (loss or substantial decrease in induction of α 1-anti-chymotrypsin synthesis in HepG2 cells, and of proliferation of Ba/F3-130-11 α cells). Only one of the mutants, namely R135E, which results from the replacement of a site II hydrophilic amino acid by a still hydrophilic but oppositely-charged amino acid,

30 appeared to potentially constitute a hyperagonistic IL-11 mutant.

There thus remains a need for a method to efficiently produce IL-11 agonists, and to obtain IL-11 agonists that would prove to be active *in vivo*.

SUMMARY OF THE INVENTION:

5

The inventors have designed and produced IL-11 muteins wherein the hydrophobicity at site I has been substantially increased by replacement of at least two IL-11 site I hydrophilic amino acids by hydrophobic counterparts. The muteins have been characterized in terms of structure, affinity, specificity and bioactivity. Electrophoretic analysis, gel filtration, infrared spectroscopy and circular dichroism indicate that these new proteins are more compact than wild-type IL-11.

15

The IL-11 muteins of the invention bind to IL-11R α with an enhanced affinity (a three-fold enhanced affinity has been measured) and retain the ability to recruit gp130 through site II.

20

As an advantageous feature, they retain the ability to induce *in vitro* proliferation of various IL-11 dependent cells. A mutein of the invention; namely the H182V+D186A hIL-11 mutein, has further been shown to be 60 to 400 fold more active than wild-type IL-11 on the *in vitro* proliferation of 7TD1 murine hybridoma cells.

25

The muteins of the invention also advantageously retain *in vivo* biological activity. Their *in vivo* biological activity can further be much higher than wild-type IL-11. An injection of the H182V+D186A hIL-11 mutein at a 10-fold lower dose than the wild-type hIL-11 has been shown to delay the death of irradiated mice for the same duration.

30

Compared to single-point mutation IL-11 muteins such as a D186A IL-11 mutein, the double point muteins of the invention prove to have *in vitro* and *in vivo* unexpected effect and advantages. They notably induce much higher survival rates upon exposure to radiation (*i.e.* upon inhibition of microvascular endothelial apoptosis); see comparative illustrative data described in example 3 below, and enclosed Figures 35-36.

The muteins of the invention are therefore useful in every biological, medical or clinical application in which wild-type IL-11 is useful, and can even show an enhanced

efficiency. The muteins of the invention are more particularly useful in radioprotection (e.g. radioprotection of the small intestine during abdominal irradiation), in decreasing chemotherapy deleterious effects (e.g. during 5-fluoroUracil chemotherapy), in anti-inflammatory therapy, in resistance to septic shock, to diabetes, and in hematopoiesis stimulation.

BRIEF DESCRIPTION OF THE DRAWINGS:

10 **Figure 1** is a reprint of AY207429 accession entry from the NCBI website (<http://www.ncbi.nlm.nih.gov/entrez>) giving the nucleotide and amino acid wild-type human IL-11 (hIL-11) sequences and characteristics (SEQ ID NO:73, and SEQ ID NO:1, respectively).

15 **Figure 2** shows the complete wild-type human, macaque, mouse and rat IL-11 amino acid sequences (SEQ ID NO:1-4).

Figure 3 shows the wild-type human, macaque, mouse and rat IL-11 amino acid sequences deleted from the first 34 N-terminal amino acids (SEQ ID NO:5-8). H182 and D186 are underlined.

20 **Figure 4** shows hIL-11 muteins of the invention (SEQ ID NO:9-13), which derive from the 34aa-deleted wild-type hIL-11 by replacement of the wild-type H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 5 shows hIL-11 muteins of the invention (SEQ ID NO:14-18), which derive from wild-type hIL-11 deleted from its first 21 amino acids, by replacement of the wild-type H182 and D186 by hydrophobic amino acids (shown underlined).

25 **Figure 6** shows hIL-11 muteins of the invention (SEQ ID NO:19-23), which derive from complete wild-type hIL-11, by replacement of the wild-type H182 and D186 by hydrophobic amino acids (shown underlined).

30 **Figure 7** shows IL-11 muteins of the invention (SEQ ID NO:24-28), which derive from 34aa-deleted wild-type macaque IL-11, by replacement of the wild-type H182 and D186 by hydrophobic amino acids.

Figure 8 shows IL-11 muteins of the invention (SEQ ID NO:29-33), which derive from the wild-type macaque IL-11 deleted from the first 21 N-terminal amino acids, by replacement of the wild-type H182 and D186 by hydrophobic amino acids.

Figure 9 shows IL-11 muteins of the invention (SEQ ID NO:34-38), which derive from complete wild-type macaque IL-11, by replacement of the wild-type H182 and D186 by hydrophobic amino acids.

Figure 10 shows IL-11 muteins of the invention (SEQ ID NO:39-43), which derive from the wild-type mouse IL-11 deleted from the first 34 N-terminal amino acids, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 11 shows IL-11 muteins of the invention (SEQ ID NO:44-48), which derive from the wild-type mouse IL-11 deleted from the first 21 N-terminal amino acids, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 12 shows IL-11 muteins of the invention (SEQ ID NO:49-53), which derive from the complete wild-type mouse IL-11, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 13 shows IL-11 muteins of the invention (SEQ ID NO:54-58), which derive from the wild-type rat IL-11 deleted from the first 34 N-terminal amino acids, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 14 shows IL-11 muteins of the invention (SEQ ID NO:59-63), which derive from the wild-type rat IL-11 deleted from the first 21 N-terminal amino acids, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 15 shows IL-11 muteins of the invention (SEQ ID NO:64-68), which derive from the complete wild-type rat IL-11, by replacement of H182 and D186 by hydrophobic amino acids (shown underlined).

Figure 16A shows the joined CDS sequence (SEQ ID NO:69) for human complete wild-type IL-11, as defined in AY207429 NCBI nucleotide entry, and the joined CDS sequence (SEQ ID NO:70) for the hIL-11 muteins of the invention which derive from the 34aa-deleted hIL-11.

Figure 16B shows the joined CDS sequence (SEQ ID NO:71) for the hIL-11 muteins of the invention which derive from the 21aa-deleted hIL-11, and the joined CDS sequence (SEQ ID NO:72) for the hIL-11 muteins of the invention which derive from the complete hIL-11.

Figure 17 shows the AY207429 NCBI entry nucleotide sequence mutated in accordance with the present invention (codons $n_1n_2n_3$ and $n_4n_5n_6$ which replace the wild-type cac and gac are shown underlined).

Figure 18 shows the mRNA sequence (SEQ ID NO:75) of a mutein of the invention,
5 which derives from hIL-11 (codons $n_1n_2n_3$ and $n_4n_5n_6$ are shown underlined).

Figure 19 shows the gene sequence (SEQ ID NO:76) of a IL-11 mutein of the invention which derive from hIL-11 (codons $n_1n_2n_3$ and $n_4n_5n_6$ are shown underlined).

Figure 20 shows the % of mouse survival par days of exposure to irradiation at 15 Gy (upper curve = mice treated with 3.2 micrograms of recombinant but non-mutated IL-
10 11; lower curve = non-treated control mice).

Figure 21 shows the % of mouse survival per days of exposure to irradiation at 15 Gy (upper curves = mice treated with 3.2 micrograms of recombinant but non-mutated IL-11, or with 0.32 microgram of a H182V+D186A mutein of the invention –“HVDA”-; lower curves = mice treated with 0.32 microgram of recombinant but non-mutated IL-
15 11, or non-treated control mice).

Figure 22 shows the parental (non-mutated) nucleotide sequence (SEQ ID NO:77) of a recombinant IL-11 (FPΔIL-11), and its parental (non-mutated) amino acid sequence (SEQ ID NO:78).

Figure 23 shows the nucleotide sequence of FPΔIL-11 mutated in accordance with the
20 present invention (SEQ ID NO:79), and the mutated corresponding amino acid sequence (SEQ ID NO:80 of the invention)

Figure 24 shows the primers used for inverse PCR mutagenesis of FPΔIL-11.

Figures 25A and 25B show a human wild-type IL-11 3D-model.

In figure 25A, a 3D model of the IL-11 based on cristallographic data obtained for
25 CNTF, as described by Tacken *et al* [1999] is shown. Figure 25B shows a site I view of the IL-11 model. Positively charged amino acids (Arg, Lys) are coloured in blue, negatively charged (Asp, Glu) are in red, hydrophilics in grey and hydrophobic in yellow.

Figure 26 shows the expression of FPΔIL-11 and of the H182V+D186A mutein
30 analysed by SDS-PAGE.

BL21 *E. coli* were transformed with pET-22b(+) vector encoding FPΔIL-11 and H/V-D/A mutein or empty vector (E). After induction (i, induced; n, not induced) of protein

production, bacteria were lysed as described in Experimental. Supernatants (100 µg of total protein per lane) were then analysed by SDS-PAGE and colored by Coomassie blue.

Figure 27 shows infrared spectra of FPΔIL-11 (top) and of H182V+D186A (bottom) in the 1800-1400 cm⁻¹ frequency range.

The absorbance is reported in mOD. The absorbance scale is given for the bottom spectrum. The upper spectrum has been offset for clarity.

Figure 28 shows the CD spectra of the FPΔIL-11 (top) and of H182V+D186A (bottom).

Figures 29A and 29B show the evolution of the integrated intensity of the amide II band as a function of the time of exposure to ²H₂O for FPΔIL-11 (circles) and for H182V+D186A (crosses).

Fitting was carried out with a three exponential decay. Panel 29A: between 0 and 20 min, panel 29B: between 0 and 700 min.

Figures 30A and 30B show gel-filtration chromatography of parental FPΔIL-11 and of mutant H182V+D186A, and their bioactivity tested from fractions collected during the chromatography.

In Figure 30A, Superdex-75 column (K16, Pharmacia Biotech) was used and calibrated with three proteins albumin (67 kDa), ovalbumin (43 kDa) and chymotrypsinogen A (25 kDa) before loading 30 µg of each analysed unlabelled protein in the presence of 50 ng of the same ³³P-labelled one as a tracer. Fifty microlitres of each collected fraction was submitted to a radio-counting. In Figure 30B, IL-11 activity was measured using the mouse hybridoma cell line 7TD1. Cells were cultivated in flat-bottom microwell plates (2 x 10³ of 7TD1 cells/well) in the presence of 0.2 µl of each eluted fraction. After 7 days of culture, the number of surviving cells was determined by colorimetric assays for hexosaminidase. Each sample was tested in triplicate and presented on average with a standard deviation.

Figures 31A and 31B show the bioactivity of parental FPΔIL-11 and mutant H182V+D186A, tested on 7TD1 (Figure 31A) and on B9 cells (Figure 31B).

Cells were cultivated in flat-bottom microwell plates (2 x 10³ of 7TD1 cells/well; 1 x 10⁴ of B9 cells/well) in the presence of serial dilutions of parental FPΔIL-11, mutein H/V-D/A, or commercial rhIL-11 (R&D). After 7 days for 7TD1 and 3 days for B9

cells culture, the number of surviving cells was determined by colorimetric assays for hexosaminidase (7TD1 cells) and for XTT (B9 cells). Each sample was tested in triplicate and presented as average with a standard deviation.

Figure 32 shows the inhibition of 7TD1 cells proliferation stimulated by FPΔIL-11 or mutant H182V+D186A, by anti-hIL-11 and anti-human gp130 neutralizing antibodies. Cells were incubated with the indicated concentrations of anti-human IL-11 monoclonal antibodies H2 (circles) and anti-human gp130 monoclonal antibodies MAB628 (squares) and B-R3 (triangles). Data points represent the means of triplicate determinations.

Figure 33 shows the expression of parental FPΔIL-11 and of its H182V+D186A mutein analysed by SDS-PAGE and immunoblotting.

BL21 *E. coli* were transformed with empty vector (mock) or expression vector encoding parental FPΔIL-11 or mutated proteins as indicated in the figure. After induced expression of the proteins, cells were lysed by sonication and lysates (100 µg of total protein per lane) were analysed by SDS-PAGE (left) and immunoblotting (right) using a polyclonal antibody raised against IL-11 (BAF 218).

Figure 34 shows the proliferation of 7TD1 cells in response to FPΔIL-11 and its H182V+D186A mutein.

7TD1 cells were incubated in the presence of serial dilutions of *E. coli* lysate containing mock, FPΔIL-11 or muteins, which were previously adjusted to 2 µg/ml. After 7 days of culture, the number of cells was determined by a colorimetric assay for hexosaminidase.

Figure 35 gives an *in vitro* comparative demonstration of an advantageous aspect of the muteins of the invention, by showing the respective proliferation levels shown by 7TD1 cells (ICLC accession number = HYL96001) in response to increasing doses of wild-type IL-11 (square symbols), or of H/V-D/A muteins of the invention (triangle symbols), or of D/A muteins (circle symbols).

Figure 36 gives an *in vivo* comparative demonstration of an advantageous aspect of the muteins of the invention, by showing the respective percent survivals of 1.5 Gy/min irradiated mice after injection of IL-11 at 320 ng (square symbols) or at 3.2 microgrammes (lozenge symbols), or after injection of the H/V-D/A muteins of the invention at 320 nanogrammes (circle symbols), or after injection of D/A muteins at 320 nanogrammes (triangle symbols).

DETAILED DESCRIPTION :

IL-11 signalling is at present time known to be dependent on the formation of a
5 ligand/receptor complex which comprises IL-11, IL-11R α subunit (responsible for the
specificity of interaction) and gp130 receptor β -subunit (responsible for signal
transduction). The interaction between IL-11 and its receptor α -subunit occurs at its
recently assigned site I (Tacke *et al.* 1999, cited *supra*, and incorporated herein by
reference).

10

Activity of IL-11 requires binding to α receptor subunit (IL-11R α) that provides ligand
specificity in a functional multimeric signal-transduction complex with gp130, the
common receptor subunit for the cytokine family including IL-6, vIL-6, CNTF (Ciliary
Neurotrophic Factor), LIF (Leukaemia Inhibitory factor), OSM (Oncostatin M), CT-1
15 (Cardiotrophin) and NNT-1/BSF-3 (Novel neurotrophin-1/B cell-stimulating factor-3).
It is believed that IL-11 first interacts with IL-11R α with a low affinity ($K_d = 10$ nM)
and that the IL-11/IL-11R α complex subsequently interacts with gp130 to form a high
affinity ($K_d = 300$ -800 pM) and signal-transducing complex.

Three sites, responsible for the interaction with the receptor subunits have been assigned
20 for IL-11 [Grotzinger, J., Kurapkat, G., Wollmer, A., Kalai, M. and Rose-John, S.
(1997) The family of the IL-6-type cytokines: specificity and promiscuity of the
receptor complexes. *Proteins* 27, 96-109 ; Tacke, I., Dahmen, H., Boisteau, O.,
Minvielle, S., Jacques, Y., Grotzinger, J., Kuster, A., Horsten, U., Blanc, C., Montero-
Julian, F. A., Heinrich, P. C. and Muller-Newen, G. (1999) Definition of receptor
25 binding sites on human interleukin-11 by molecular modelling-guided mutagenesis.
Eur. J. Biochem. 265, 645-655].

Site I, which essentially consists of amino acids at the end of the AB-loop and the
C-terminal part of the D-helix, is implicated in the interaction with the IL11R α subunit.
Site II, which essentially consists of amino acids from the A and C helices and site III,
30 which essentially consists of the N-terminal part of the D-helix and residues from the
beginning of the AB-loop, are responsible for gp130 (β -subunit) recruitment (Figure
25).

The inventors found that IL-11 muteins can be produced that have an increased affinity for IL-11R α , that have retained affinity for gp130, and that have retained or improved IL-11 biological activity.

5

The inventors demonstrate that such agonistic IL-11 muteins are obtainable by substantially increasing the hydrophobicity of IL-11 site I, which thereby makes the structure of the IL-11 molecule more compact. Increasing the hydrophobicity of IL-11 site I can be achieved by replacement of IL-11 site I hydrophilic amino acids by hydrophobic counterparts. It further appeared to the inventors that at least two of such hydrophilic amino acids should be replaced by hydrophobic counterparts.

The inventors notably demonstrate that site I of human wild-type IL-11 comprises two hydrophilic amino acids (His182 and Asp186), and that substituting both of them by hydrophobic counterparts (*e.g.* substituting His182 and Asp186 by Valine and Alanine, respectively) leads to a hIL-1 mutein with increased affinity for IL-11R α , increased specificity and increased *in vitro* and *in vivo* bioactivity.

The fact that the muteins of the invention have such excellent properties and effects is all the more surprising and unexpected since opposite properties and effects are obtained when only one of these two hydrophilic amino acids is substituted.

Indeed, Czupryn *et al.* 1995 (cited *supra*) describes that substituting D186 by A (without substituting H186) results in a human IL-11 mutein which has, with respect to the wild-type human IL-11, a highly decreased biological activity: a 500 fold decrease in biological activity has been measured on murine plasmacytoma cell line T10.

This document hence disclosed the D/A mutation as a highly undesired candidate mutation to obtain a mutein with increased biological activity.

In fact, the inventors now further demonstrate that one cannot directly rely on results obtained *in vitro* from cell lines to reliably assume that a given mutation is a good or a bad candidate to obtain a mutein with increased efficiency: the same D186A mutation, but on a FPΔIL-11 protein (Flag tag + deletion of N-terminal proline-rich region, see the examples below), has been assayed by the inventor on another cell line (cell line 7TD1,

see the examples below), and appears to induce an increase in biological activity for this cell line.

As a matter of fact, the inventors have performed *in vivo* experiments which confirm that, compared to single-point mutation IL-11 muteins such as a D186A IL-11 mutein,
5 the double point muteins of the invention prove to have *in vivo* unexpected effect and advantages. They notably induce much higher survival rates upon exposure to radiation (*i.e.* upon inhibition of microvascular endothelial apoptosis); see comparative illustrative data described in example 3 below, and enclosed Figures 35-36.

10 It can also be noted that a mutein of the invention for which both His182 and Asp186 are mutated (by Val and Ala, respectively) is surprisingly and unexpectedly a lot more biologically active than human wild-type IL-11: a 60 to 400 fold increase in *in vitro* cell proliferation has been measured on 7TD1 murine hybridoma cells.

Furthermore, as a very advantageous and in fact highly essential feature, the muteins of
15 the invention induce an increase of biological activity *in vivo* in an animal, such as a mammal (a 10-fold increase in radioprotection *in vivo* efficiency has been measured on irradiated mice with H/V-D/A, see the examples below).

The present invention thus provides with a method to produce an IL-11 agonist, which
20 comprises producing an IL-11 mutein wherein site I hydrophobicity has been increased by replacement of at least two non-hydrophobic amino acids which are part of the wild-type IL-11 epitope for IL-11R α by hydrophobic ones.

As said two non-hydrophobic amino acids are part of the wild-type IL-11 epitope for
25 IL-11R α , they belong to what is known as IL-11 site I (= end of AB-loop and C-terminal part of the D-helix).

Said at least two non-hydrophobic amino acids most preferably are surface-exposed.

The mutein molecule is thereby rendered more compact.

30 It has retained the ability to bind to IL-R α through its mutated site I, and has also retained the ability to bind to the other components of the IL-11 signal transducing complex, and notably to gp130 through site II and site III of the mutein.

It has also retained the ability to induce *in vitro* proliferation of IL-11 dependent cells, such as 7TD1 murine hydridoma cells available from the ICLC (Interlab Cell Line Collection of the Istituto Nazionale per la Ricerca sul Cancro ; L.go R. Benzi, 10 ; 16132 Genova, Italy ; see <http://www.iclc.it/Lista.html> and
5 <http://www.biotech.ist.unige.it> ; ICLC Catalogue accession number = HYL96001).

It has also retained *in vivo* bioactivity, such as *e.g.* the ability to protect against radiation.

- 10 As the muteins of the invention have at least retained IL-11 affinity and bioactivity, they can be referred to as IL-11 agonist or hyperagonist.

To determine whether a given IL-11 amino acid is or not part of the epitope for IL-11R α , and whether it is or not surface-exposed, the person of ordinary skill in the art
15 can proceed in line with what is described in Tacke *et al.* 1999 (cited *supra*). It may *e.g.* comprise the use of a three-dimensional structure representation of said IL-11 to locate said given amino acid so that it can be determined whether it belongs or not to site I (= epitope for IL-11R α) and whether it is or not surface-exposed (see Figures 1A and 1B of said Tacke *et al.* 1999, as well as the section within this publication which is
20 entitled “*Generation of a molecular model of interleukin-11 and selection of amino acid residues for site-directed mutagenesis*”, the content of which is herein incorporated by reference).

Nucleotide and amino acid sequences of wild-type IL-11R α are available from standard
25 sequence databanks known to the person of ordinary skill in the art. Human IL-11R α sequences are thus available from the NCBI website at <http://www.ncbi.nlm.nih.gov/entrez> under the nucleotide accession number Z38102, the content of which is herein incorporated by reference. IL-11R α sequences from animal yet non-human origin, such as from mouse and rat, are also available from the NCBI
30 website at <http://www.ncbi.nlm.nih.gov/entrez> (for mouse and rat IL-11R α sequences, see under the respective nucleotide accession numbers X98519 and AF347936, the contents of which are herein incorporated by reference).

As a matrix to assay for binding to IL-11R α , soluble IL-11R α , *e.g.* the human IL-11R α -IL-2 fusion protein which is described in Blanc *et al.* 2000, can be used (Blanc *et al.* (2000) Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Ralpha) and their use in studies of human mononuclear cells. J. Immunol. Methods 241, 43-59, the content of which is herein incorporated by reference). Murine IL11-11Ralpha is available from R&D Systems (<http://www.RnDSystems.com>).

Wild-type IL-11 nucleotide and amino acid sequences are available from standard sequence databanks known to the person of ordinary skill in the art: human wild-type IL-11 sequence is described on the NCBI website at <http://www.ncbi.nlm.nih.gov/entrez> under the nucleotide accession number AY207429, the content of which is herein incorporated by reference. Human wild-type nucleotide and amino acid sequences are also shown printed from said site on the enclosed Figure 1 (SEQ ID NO:73 = AY207429 IL-11 nucleotide sequence ; SEQ ID NO: 1 = human wild-type IL-11 amino acid sequence). A wild-type hIL-11 cDNA sequence is also available from Accession Number NM57765 from the above-mentioned NCBI website.

Wild-type IL-11 sequences from animal yet non-human sources are also available from the above-mentioned NCBI website, such as *e.g.* mouse and rat IL-11 (nucleotide accession number NM 008350 and NM 133519, respectively).

The replacement of said at least two amino acids can be achieved by any standard procedure known to the person of ordinary skilled in the art. It may *e.g.* involve mutation by inverse PCR amplification as described in Stemmer W. P. and Morris S. K. 1992 [Stemmer and Morris (1992) Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis. Biotechniques 13, 214-220], of which content is herein incorporated by reference.

The choice of appropriate primers is made by making use of the common knowledge in the field applied to the design of oligonucleotides which have such a sequence that they can have the function of a primer for a given IL-11 template sequence, while having the ability to introduce at least two point mutations in the amplicon with respect to the template sequence (see Stemmer and Morris 1992, cited *supra*).

An illustrative procedure of such an IL-11 mutagenesis is described in example 1 below.

The production of the mutein can be achieved by any conventional procedure known to the person of ordinary skill in the art of producing proteins in general, and of producing wild-type IL-11 in particular. It may *e.g.* comprise the production of a plasmid comprising a sequence coding for the mutein (for the construction of a plasmid, see Wang, X. M., Wilkin, J. M., Boisteau, O., Harmegnies, D., Blanc, C., Vandenbussche, P., Montero-Julian, F. A., Jacques, Y. and Content, J. (2002) Engineering and use of ³²P-labelled human recombinant interleukin-11 for receptor binding studies. Eur. J. Biochem. 269, 61-68, the content of which is herein incorporated by reference), and transforming a host cell such as *E. coli* with this plasmid so that the the mutein is expressed by the transformed cells, from which it can be recovered and isolated. An illustrative procedure of mutein production is described in example 1 below.

15

Non-hydrophobic amino acids (*e.g.* hydrophilic amino acids) have a side chain that is electrically charged, or that is an uncharged yet polar chain. They notably comprise:

- Cystein (symbol = C or Cys),
- Tyrosine (symbol = Y or Tyr),
- 20 - Histidine (symbol = H or His),
- Lysine (symbol = K or Lys),
- Arginine (symbol = R or Arg),
- Glutamine (symbol = Q or Gln),
- Asparagine (symbol = N or Asn),
- 25 - Glutamic acid (symbol = E or Glu),
- Aspartic acid (symbol = D or Asp),
- Serine (symbol = S or Ser),
- Threonine (symbol = T or Thr).

30 Hydrophobic amino acids have a side chain that is non-polar and uncharged. They notably comprise:

- Valine (symbol = V or Val),

- Alanine (symbol = A or Ala),
- Proline (symbol = P or Pro),
- Leucine (symbol = L or Leu),
- Isoleucine (symbol = I or Ile),
- 5 - Methionine (symbol = M or Met),
- Tryptophan (symbol = W or Trp),
- Phenylalanine (symbol = F or Phe).

Human IL-11 site I is composed of a hydrophobic cluster which comprises a limited
10 number of hydrophilic amino acids: these site I hydrophilic amino acids notably
comprise H in position 182 and D in position 186 (see SEQ ID NO:1 on Figure 1 and on
Figure 2).

In accordance with the present invention, histidine (H) in position 182 and aspartic acid
15 (D) in position 186 are most preferred as wild-type hIL-11 mutation targets to be
replaced by hydrophobic amino acids.

Similarity in terms of sterical hindrance, structure and/or size may in choosing those
hydrophobic amino acids which are more appropriate to replace said H and D targets.

The most preferred hydrophobic amino acids for replacing IL-11 site I hydrophilic
20 amino acids comprise valine (V) and alanine (A).

The mutein obtained by replacement of H182 by V and of D186 by A has proven to be
an IL-11 hyperagonist : compared to wild-type hIL-11, it has a three-fold increased
affinity for IL-11R α , while still retaining the ability to recruit gp130 ; it is 60 to 400
25 fold more active on the proliferation of the murine hybridoma cell line 7TD1, and the
mutein reaches an *in vivo* radioprotection iso-effect at a ten-fold lower dose than
the wild-type IL-11 (ten fold less mutein than wild-type IL-11 is needed to achieve the
same *in vivo* radioprotection effect) ; see examples 1 and 2 below.

30 In macaque, mouse and rat wild-type IL-11, those hydrophilic amino acids which at
present are known to belong to site I are also H182 and D186.

The N-terminal of wild-type IL-11 protein begins with a signal peptide of 21 amino acids, directly followed by a proline-rich region of 13 amino acids. These first 34 N-terminal amino acids are not necessary to IL-11 biological activity : they can therefore be deleted. Figure 3 shows the wild-type human, macaque, mouse and rat IL-11 sequences respectively deleted from their first 34 N-terminal amino acids (SEQ ID NO: 5-8, respectively).

The present invention thus provides IL-11 muteins, the sequence of which comprises a sequence which is derivable from a wild-type IL-11 by replacement of the hydrophilic amino acids in positions 182 and 186 (positions computed by reference to the complete wild-type sequence) by X_1 and X_2 respectively, X_1 and X_2 being chosen from the group comprising:

- Valine (symbol = V or Val),
- Alanine (symbol = A or Ala),
- 15 - Proline (symbol = P or Pro),
- Leucine (symbol = L or Leu),
- Isoleucine (symbol = I or Ile),
- Phenylalanine (symbol = F or Phe),
- Methionine (symbol = M or Met), and
- 20 - Tryptophan (symbol = W or Trp),

and optionally by deletion of a N-terminal portion that does not exceed the first 34 N-terminal amino acids.

As the first 34 N-terminal amino acids are not necessary to IL-11 biological activity, a N-terminal portion that does not exceed the first 34 N-terminal amino acids can indeed be deleted without substantially altering the functions of the muteins of the invention.

The present invention thus relates to IL-11 muteins, the sequence of which comprises a sequence chosen from the group comprising SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, SEQ ID NO:54 shown on Figures 4, 7, 10, 13, respectively (IL-11 muteins which derives from 34aa-deleted wild-type IL-11 from human, macaque, mouse and rat origin, respectively).

The present invention also encompasses those equivalent IL-11 muteins which comprise a sequence of at least 80%, preferably at least 90% identity with the above-mentioned SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, provided that X₁ and X₂ are as above-defined (*i.e.* hydrophobic amino acids), and that the resulting
5 protein has retained the ability of wild-type IL-11 to induce proliferation of an IL-11 dependent cell line, such as *e.g.* the 7TD1 murine hybridoma cell line.

Illustrative and useful muteins of the invention comprise those for which X₁ and X₂ are V or A.

- 10 The present invention therefore more particularly encompasses those IL-11 muteins which comprise a sequence corresponding to a wild-type IL-11 deleted from those N-terminal amino acids which are not necessary to its biological activity, wherein the amino acids in positions 182 and 186 have been replaced by V and A, A and V, V and V, or A and A, respectively.
- 15 The present invention thus relates to those IL-11 muteins which comprise a sequence of SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, wherein X₁=V and X₂=A, *i.e.* to those IL-11 muteins which comprise a sequence of SEQ ID NO:10 (deriving from human IL-11), of SEQ ID NO:25 (deriving from macaque IL-11), of SEQ ID NO:40 (deriving from mouse IL-11), or of SEQ ID NO:55 (deriving from rat
20 IL-11). These SEQ ID are shown on Figures 4, 7, 10 and 13, respectively.

- The present invention also relates to those IL-11 muteins which comprise a sequence of SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, wherein X₁=A and X₂=V, *i.e.* to those IL-11 muteins which comprise a sequence of SEQ ID NO:11
25 (deriving from human IL-11), of SEQ ID NO:26 (deriving from macaque IL-11), of SEQ ID NO:41 (deriving from mouse IL-11), or of SEQ ID NO:56 (deriving from rat IL-11). These SEQ ID are shown on Figures 4, 7, 10 and 13, respectively.

- The present invention also relates to those IL-11 muteins which comprise a sequence of
30 SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, wherein X₁=V and X₂=V, *i.e.* to those IL-11 muteins which comprise a sequence of SEQ ID NO:12 (deriving from human IL-11), of SEQ ID NO:27 (deriving from macaque IL-11), of

SEQ ID NO:42 (deriving from mouse IL-11), or of SEQ ID NO:57 (deriving from rat IL-11). These SEQ ID are shown on Figures 4, 7, 10 and 13, respectively.

The present invention also relates to those IL-11 muteins which comprise a sequence of
5 SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, wherein $X_1=A$ and $X_2=A$, *i.e.* to those IL-11 muteins which comprise a sequence of SEQ ID NO:13 (deriving from human IL-11), of SEQ ID NO:28 (deriving from macaque IL-11), of SEQ ID NO:43 (deriving from mouse IL-11), or of SEQ ID NO:58 (deriving from rat IL-11). These SEQ ID are shown on Figures 4, 7, 10 and 13, respectively.

10

Illustrative and useful IL-11 muteins of the invention thus comprises those IL-11 muteins which derive from a wild-type IL-11 by deletion of the signal peptide (first 21 N-terminal amino acids), and by replacement of the amino acids in positions 182 and 186 (positions computed by reference to the complete wild-type IL-11) by the
15 hydrophobic X_1 and X_2 amino acids as above-defined.

The present invention thus encompasses those IL-11 muteins, the sequence of which comprises or consists in a sequence of SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44 or SEQ ID NO:59, wherein X_1 and X_2 are as above-defined. These SEQ ID are shown on Figures 5, 8, 11, and 14, respectively.

20 The sequence of SEQ ID NO:14 corresponds to the human wild-type IL-11 wherein the amino acids in positions 182 and 186 have been replaced by X_1 and X_2 , and wherein the first 21 N-terminal amino acids have been deleted (see Figure 5).

The sequence of SEQ ID NO:29 corresponds to the macaque wild-type IL-11 wherein the amino acids in positions 182 and 186 have been replaced by X_1 and X_2 , and wherein
25 the first 21 N-terminal amino acids have been deleted (see Figure 8).

The sequence of SEQ ID NO:44 corresponds to the mouse wild-type IL-11 wherein the amino acids in positions 182 and 186 have been replaced by X_1 and X_2 , and wherein the first 21 N-terminal amino acids have been deleted (see Figure 11).

The sequence of SEQ ID NO:59 corresponds to the rat wild-type IL-11 wherein the
30 amino acids in positions 182 and 186 have been replaced by X_1 and X_2 , and wherein the first 21 N-terminal amino acids have been deleted (see Figure 14).

When $X_1=V$ and $X_2=A$ in SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:59, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:15, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:60, respectively (shown on Figures 5, 8, 11, 14, respectively).

- 5 When $X_1=A$ and $X_2=V$ in SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:59, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:16, SEQ ID NO:31, SEQ ID NO:46, SEQ ID NO:61, respectively (shown on Figures 5, 8, 11, 14, respectively).

- 10 When $X_1=V$ and $X_2=V$ in SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:59, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:17, SEQ ID NO:32, SEQ ID NO:47, SEQ ID NO:62, respectively (shown on Figures 5, 8, 11, 14, respectively).

- 15 When $X_1=A$ and $X_2=A$ in SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44, SEQ ID NO:59, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:18, SEQ ID NO:33, SEQ ID NO:48, SEQ ID NO:63, respectively (shown on Figures 5, 8, 11, 14, respectively).

- The muteins of the invention which comprise or consist in a sequence of SEQ ID NO:15-18, SEQ ID NO:30-33, SEQ ID NO:45-48, SEQ ID NO:60-63, respectively are preferred muteins of the invention. Those muteins of the invention which comprise or
20 consist in a sequence of SEQ ID NO:15, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:60, respectively are most preferred.

- 25 Illustrative and useful IL-11 muteins of the invention are also those muteins of the invention that derive from complete wild-type IL-11 by replacement of the amino acids in positions 182 and 186 by the hydrophobic X_1 and X_2 amino acids as above defined.

Such illustrative and useful IL-11 muteins thus comprise those that comprise or consist in a sequence of SEQ ID NO:19, SEQ ID NO:34, SEQ ID NO:49, or SEQ ID NO:64, wherein X_1 and X_2 are as above defined.

- 30 The sequence of SEQ ID NO:19 corresponds to human complete wild-type IL-11 wherein H182 and D186 have both been replaced by X_1 and X_2 as above defined. It is shown on Figure 6.

The sequence of SEQ ID NO:34 corresponds to macaque complete wild-type IL-11 wherein H182 and D186 have both been replaced by X₁ and X₂ as above defined. It is shown on Figure 9.

The sequence of SEQ ID NO:49 corresponds to mouse complete wild-type IL-11
5 wherein H182 and D186 have both been replaced by X₁ and X₂ as above defined. It is shown on Figure 12.

The sequence of SEQ ID NO:64 corresponds to rat complete wild-type IL-11 wherein H182 and D186 have both been replaced by X₁ and X₂ as above defined. It is shown on Figure 15.

10

When X₁=V and X₂=A in SEQ ID NO:19, SEQ ID NO:34, SEQ ID NO:49, SEQ ID NO:64, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:20, SEQ ID NO:35, SEQ ID NO:50, SEQ ID NO:65, respectively (shown on Figures 6, 9, 12, 15, respectively).

15 When X₁=A and X₂=V in SEQ ID NO:19, SEQ ID NO:34, SEQ ID NO:49, SEQ ID NO:64, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:21, SEQ ID NO:36, SEQ ID NO:51, SEQ ID NO:66, respectively (shown on Figures 6, 9, 12, 15, respectively).

When X₁=V and X₂=V in SEQ ID NO:19, SEQ ID NO:34, SEQ ID NO:49, SEQ ID
20 NO:64, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:22, SEQ ID NO:37, SEQ ID NO:52, SEQ ID NO:67, respectively (shown on Figures 6, 9, 12, 15, respectively).

When X₁=A and X₂=A in SEQ ID NO:19, SEQ ID NO:34, SEQ ID NO:49, SEQ ID
25 NO:64, respectively, the muteins of the invention comprise or consist in a sequence of SEQ ID NO:23, SEQ ID NO:38, SEQ ID NO:53, SEQ ID NO:68, respectively (shown on Figures 6, 9, 12, 15, respectively).

The muteins of the invention which comprise or consist in a sequence of SEQ ID NO:20-23, SEQ ID NO:35-38, SEQ ID NO:50-53, SEQ ID NO:65-68, respectively are preferred muteins of the invention. Those muteins of the invention which comprise or
30 consist in a sequence of SEQ ID NO:20, SEQ ID NO:35, SEQ ID NO:50, SEQ ID NO:65, respectively are most preferred.

The present invention also encompasses any nucleic acid, such as DNA or RNA, coding for a mutein of the invention.

It notably encompasses any nucleic acid, such as DNA, which comprises the joined
5 CDS (coding sequences) of a wild-type IL-11 appropriately mutated in accordance with the present invention.

The joined CDS sequence of human wild-type IL-11 are shown as SEQ ID NO:69 on Figure 16A (codon CAC coding for H182, and codon GAC coding for D186 are underlined).

10 Appropriate mutations in accordance with the present invention comprise replacing said cac and gac wild-type codons by codon $n_1n_2n_3$ and $n_4n_5n_6$ respectively, wherein both $n_1n_2n_3$ and $n_4n_5n_6$ code for hydrophobic amino acids, *i.e.* the above-defined X1 and X2 amino acids.

Accordingly, $n_1n_2n_3$ and $n_4n_5n_6$ are both chosen from the group comprising the
15 nucleotide codons which code for Valine (symbol = V or Val), Alanine (symbol = A or Ala), Proline (symbol = P or Pro), Leucine (symbol = L or Leu), Isoleucine (symbol = I or Ile), Phenylalanine (symbol = F or Phe), Methionine (symbol = M or Met), and Tryptophan (symbol = W or Trp). It follows that, having taken into account the degeneracy of the genetic code, $n_1n_2n_3$ and $n_4n_5n_6$ are both chosen from the group
20 comprising the following codons:

- GCT, GCC, GCA, GCG,
- GTT, GTC, GTA, GTG,
- TTA, TTG, CTT, CTC, CTA, CTG,
- ATT, ATC, ATA,
- 25 - TTT, TTC,
- ATG,
- CCT, CCC, CCA, CCG,
- TGG.

The present invention thus notably encompasses any nucleic acid (*e.g.* DNA) which
30 comprises the sequence of SEQ ID NO:72 shown on Figure 16B, wherein $n_1n_2n_3$ and $n_4n_5n_6$ are as above-defined.

When, in accordance with the present invention, the wild-type IL-11 has been deleted from its first 21 N-terminal amino acid (see SEQ ID NO:14-18 on Figure 5), or from its first 34 N-terminal amino acid (see SEQ ID NO:9-13 on Figure 4), the corresponding joined CDS sequence is deleted from the corresponding codons.

- 5 The present invention thus encompasses any nucleic acid (*e.g.* DNA) which comprises the sequence of SEQ ID NO:71 or of SEQ ID NO:70 shown on Figure 16B and 16A, respectively, wherein $n_1n_2n_3$ and $n_4n_5n_6$ are as above-defined.

- 10 The present invention thus more particularly encompasses any nucleic acid (*e.g.* DNA) which comprises or consists in the sequence of SEQ ID NO:76 or of SEQ ID NO:74, which are shown on Figures 19 and 17, respectively, and wherein the codons $n_1n_2n_3$ and $n_4n_5n_6$ are as above-defined.

- The sequence of SEQ ID NO:76 corresponds to the human IL-11 wild-type gene (as defined in AY207429 NCBI accession sequence by position 1582 to position 7566),
15 appropriately mutated in accordance with the present invention, *i.e.* wherein the wild-type codons cac and gac coding for H182 and D186 have been replaced by $n_1n_2n_3$ and $n_4n_5n_6$ as above-defined.

- The sequence of SEQ ID NO:74 corresponds to the nucleotide sequence of SEQ ID NO:73 (AY207429 NCBI sequence), appropriately mutated in accordance with the
20 present invention, *i.e.* wherein the wild-type codons cac and gac coding for H182 and D186 have been replaced by $n_1n_2n_3$ and $n_4n_5n_6$ as above-defined.

- Following the same mutational scheme, similarly-mutated sequences can be obtained from wild-type IL-11 non-human DNA, such as macaque, mouse and rat wild-type IL-11 DNA, and such similarly-mutated sequences are encompassed by the present
25 invention.

- The present invention also encompasses any nucleic acid comprising or consisting a RNA sequence deriving from a wild-type IL-11 RNA sequence appropriately mutated in accordance with the present invention, *i.e.* wherein the wild-type codons CAC and
30 GAC coding for H182 and D186 have been replaced by $n_1n_2n_3$ and $n_4n_5n_6$ as above-defined.

The present invention thus particularly relates to the sequence of SEQ ID NO:75, shown on Figure 18. The sequence of SEQ ID NO:75 corresponds to the mRNA sequence of human wild-type IL-11 (as defined in AY207429 NCBI accession sequence by joined sequence 1582-1651, 3014-3186, 3386-3472, 3584-3745, 5778-7566), appropriately
5 mutated in accordance with the present invention ($n_1n_2n_3$ and $n_4n_5n_6$ are underlined).

The present invention also relates to any mutated RNA sequence which is similarly obtained from wild-type non-human IL-11 RNA, such as macaque, mouse, rat IL-11.

According to a further aspect of the present invention, the application also relates to any
10 transfection vector, such as *e.g.* a plasmid, which comprises a nucleic acid of the present invention, *i.e.* a nucleic acid coding for an IL-11 mutein of the invention.

Illustrative and useful transfection vectors of the invention comprise those that comprise as an insertion sequence a sequence comprising or consisting of a sequence which derives from a sequence coding for a wild-type IL-11 by replacement of the codons
15 coding for the hydrophilic amino acids in positions 182 and 186 by the codons $n_1n_2n_3$ and $n_4n_5n_6$ as above-defined, and possibly by deletion of codons that are not necessary to an biological activity of the IL-11 type, such as *e.g.* by deletion of the codons which in the complete wild-type IL-11 code for the N-terminal signal peptide and/or the those N-terminal codons corresponding to proline-rich regions.

20 Illustrative and useful transfection vectors of the invention thus can comprise a sequence comprising or consisting of a sequence which derives from a sequence coding for a wild-type IL-11 by replacement of the codons coding for the hydrophilic amino acids in positions 182 and 186 by the codons $n_1n_2n_3$ and $n_4n_5n_6$ as above-defined, and by deletion of those codons of the complete wild-type IL-11 that code for the first 21 N-
25 terminal amino acids or for the first 31 or 34 N-terminal amino acids.

A short nucleotide sequence coding for a Flag tag, such as Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys, followed by another short nucleotide sequence coding for a consensus sequence that can be recognized and phosphorylated by a kinase (such as Arg-Arg-Ala-Ser-Val-Ala that can be recognized and phosphorylated on the serine residue by the
30 bovine heart kinase) can be added at one end of the IL-11 mutein encoding nucleic acid, *e.g.* at the 5' part of it, in lieu et place of the codons which in the complete wild-type IL-11 code for the first 31 N-terminal amino acids.

Such a transfection vector is described in example 1 below. An illustrative and useful insertion sequence for such a vector is shown on Figure 23 under SEQ ID NO:79 (wild-type human IL-11 which has been mutated in accordance with the present invention by the above-defined $n_1n_2n_3$ and $n_4n_5n_6$ codons, which has been deleted from the codons coding for the first 31 N-terminal amino acids, and to which codons coding for a Flag tag and for consensus sequence recognized by the heart bovine kinase have been added: in Figure 23, the Flag tag is boxed, and the consensus sequence for kinase is underlined).

10 According to a further aspect of the invention, the present application relates to any cell comprising a nucleic acid of the invention, and/or which has been transfected by a transfection vector of the invention, and/or which express a mutein of the invention.

Such cells may *e.g.* be used to produce and isolate IL-11 muteins of the invention. Any cell that is available to the person of ordinary skill in the art as appropriate host cell may
15 used to be transformed by a transfection vector of the invention, so that the transformed cell thereby produced can express a mutein of the invention. Appropriate standard host cells *e.g.* comprise *E. coli* cells, such as *e.g.* the *E. coli* BL21(DE3) strain (available from Novagen).

The invention thus encompasses a method to produce an IL-11 mutein of the invention
20 which comprises culturing a cell of the invention in a suitable culture medium (*e.g.* for a *E. coli* transformed cell, in Luria-Bertani medium), and isolating said IL-11 mutein from said cell.

The present invention thus encompasses any cell transformed with a nucleic acid
25 sequence of the invention in operative association with an expression control sequence capable of directing replication and expression of said nucleic acid sequence.

As indicated above and illustrated below, the IL-11 muteins of the invention have at least retained an ability to bind to IL-11R α and gp130, and to induces an *in vitro* and *in vivo* activity of the type induced by wild-type IL-11. They thus are all useful in every
30 application in which wild-type IL-11 is considered as useful.

Exemplary biological or medical applications of IL-11 are described in US 6,126,933 ; WO 00/74707 ; US 5,460,810 ; US 6,540,993 ; US 5,215,895 ; WO 00/53214 ; the contents of which are herein incorporated by reference.

5 The IL-11 muteins of the invention for which H182 and D186 have been replaced by Val and Ala further prove to be highly more efficient than wild-type IL-11, and may thus be referred to as IL-11 hyperagonists. For example, the H182V+D186A muteins of the invention (*i.e.* the muteins which comprise a sequence of SEQ ID NO:10, SEQ ID NO:25, SEQ ID NO:40, or SEQ ID NO:55, or conservative variants thereof) bind to IL-11R α with a three-fold enhanced affinity compared to wild-type IL-11, are 60 to 400 fold more active on the proliferation of 7TD1 murine hydridoma cells than wild-type IL-11, and are required at a ten fold lower dose to induce the same *in vivo* radioprotection wild-type IL-11 iso-effect (see examples 1 and 2 below).

10 The present application therefore also encompasses the IL-11 muteins of the invention as agents useful for improving resistance to radiation, such as resistance to radiation therapy for the treatment of cancer or for the preparation of patients for bone marrow transplantation.

20 The present application also encompasses the IL-11 muteins of the invention as agents useful for improving resistance to deleterious effects induced by chemotherapy for the treatment of cancer.

It more particularly relates to the IL-11 muteins of the invention as anti-thrombocytopenia agents.

25 The IL-11 muteins of the invention can also be useful as anti-inflammatory agents, and/or as agents to induce or stimulate hematopoiesis, neurogenesis, osteoclastogenesis, and/or female fertility.

30 Going into details of the anti-inflammatory aspect of the invention, it can be emphasized that, as known by the skilled person, wild-type IL-11 has septic shock-protective and diabetes-protective activities (see introduction). It is also known by the skilled person that the underlying mechanism for these protective IL-11 activities can be found in the inhibition exerted by IL-11 on microvascular endothelial apoptosis (see *e.g.* Sheridan *et al.* 1999, "Interleukin-11 attenuates pulmonary inflammation and

vasomotor dysfunction in endotoxin-induced lung injury", Am. J. Physiol. 277 (Lung Cell. Mol. Physiol. 21): L861-L867; Nicoletti *et al.* 1999, "*Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice*", Diabetes, vol. 48, pages 2333-2339).

- 5 As it is also known that the primary lesion induced by radiation is microvascular endothelial apoptosis (*cf. e.g.* Paris *et al.* 2001, "*Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice*", Science vol. 293, pages 293-297), the muteins of the invention are useful agents for inhibiting microvascular endothelial apoptosis. The muteins of the invention hence find advantageous applications in the
- 10 prevention, and/or symptom alleviation, and/or treatment of those diseases or conditions for which inhibition of microvascular endothelial apoptosis is needed, such as septic shock and diabetes (*e.g.* type 1 diabetes). The muteins of the invention are powerful anti-inflammatory agents that most probably will be capable of down-regulating early immunodiabetogenic pathways.

15

- The present invention thus relates to any drug that comprises a therapeutically effective amount of an IL-11 mutein of the invention, or a nucleic acid of the invention, or a vector of the invention, or a cell of the invention. Such a drug may further comprise any pharmaceutically-acceptable vehicle (*e.g.* isotonic sodium chloride solution) that is
- 20 available to the person of ordinary skill in the art of preparing drugs, as well as any stabilizer, preservative, buffer, antioxidant, or additive that the person of ordinary skill will find appropriate. The drug may be produced in any form and conditioning that is appropriate to its intended mode of administration (parenteral, intravenous, subcutaneous, topical, etc.). The dosage regimen of a drug of the invention will be
- 25 determined by the attending physician considering the condition, body weight, sex, diet, age, and other medically-relevant features of the patient to be treated. As an advantageous feature of the invention, those drugs which comprise the muteins for which H182 and D186 by Val and Ala will be usually required at lower doses than would have been wild-type IL-11.

30

A drug of the invention may be useful for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.

It may also be useful for treating inflammatory bowel diseases (*e.g.* Crohn's disease, ulcerative colitis, indeterminate colitis and infectious colitis), mucositis (*e.g.* oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (*e.g.* psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (*e.g.* conjunctivitis, retinis, and uveitis).

10 It may also be useful to prevent or treat hemorrhagic shock, and to protect the gastrointestinal system during a hemorrhagic shock and resuscitation.

It may also be useful to prevent or treat an immune-mediated cytotoxicity, such as graft versus host disease or rejection of organ and tissue transplants, as well as non-immune-mediated necrotic injuries, such as localized tissue or cell injury caused by loss of blood
15 supply, corrosion, burning, or the local lesion of a disease.

The invention more particularly relates to any anti-thrombocytopenia drug, which comprises a mutein of the invention, and a therapeutically effective amount of an active principle for chemotherapy of cancer.

A drug of the invention is also useful for the prevention, symptom alleviation, or
20 treatment of any disease or condition for which microvascular apoptosis inhibition is desired, and more particularly for the prevention, symptom alleviation, or treatment of of diabetes, such as type 1 diabetes, and/or septic shock.

The following examples are given as illustrative examples, and are in no way intended
25 to restrict the scope of the present invention. More particularly, while human IL-11 muteins are described as a useful and particularly relevant illustration, any conservative variants thereof that the person of ordinary skill in the art will contemplate are encompassed by the present application.

EXAMPLE 1: production of IL-11 muteins, and characterization of their structure, affinity, specificity and cell line bioactivity.

EXPERIMENTAL

5 Bacterial strains, enzymes and chemicals

Escherichia coli DH5 α was from Invitrogen Life Technologies. BL21 (DE3) and pET-22b(+) were from Novagen. *E. coli* recombinant human IL-11 was from PeproTech Inc. (London, UK) and R & D Systems (Wiesbaden-Nordenstadt, Germany). Primers for mutagenesis were from Genset. MAB628 and anti-hIL-11 biotinylated polyclonal
10 antibody BAF218 were from R & D Systems. [γ -³²P]ATP with a specific radioactivity of ~3000 Ci/mmol was obtained from Amersham Pharmacia Biotech. Acrylamide and N,N'-methylene-bisacrylamide were from Bio-Rad. RPMI-1640, DMEM, glutamine and FCS were from Gibco-BRL. The catalytic subunit of cAMP-independent protein
15 kinase from bovine heart muscle, streptavidin conjugated alkaline phosphatase, sodium dodecyl sulfate (SDS) and anti-Flag M2 monoclonal antibody were obtained from Sigma (Bornem, Belgium).

Mutagenesis

FPAIL-11 was mutated by inverse PCR amplification of the plasmid pET-FPAIL-11 previously described in Wang *et al.* 2002, using the primers shown on Figure 24,
20 followed by a *Dpn* I digestion to eliminate the parental plasmid.
For a detailed description of the mutation by inverse PCR amplification, see Stemmer, W. P. and Morris, S.K. (1992) Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis. *Biotechniques* 13, 214-220, the content of which is herein incorporated by reference.
25 For the construction of plasmid pET-FPAIL-11, see Wang, X. M., Wilkin, J. M., Boisteau, O., Harmegnies, D., Blanc, C., Vandenbussche, P., Montero-Julian, F. A., Jacques, Y. and Content, J. (2002) Engineering and use of 32P-labelled human recombinant interleukin-11 for receptor binding studies. *Eur. J. Biochem.* 269, 61-68, the content of which is herein incorporated by reference.

Please note, in accordance with Wang *et al.* 2002, the N-terminal nucleotides encoding the first 31 amino acids of human IL-11 joined CDS shown on Figure 16A under SEQ ID NO:69 have been deleted (the first 21 signal peptide amino acids + the 10 amino acids which follow and which correspond to a proline-rich region), and replaced by a sequence encoding a Flag tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) followed by a consensus amino-acid sequence (Arg-Arg-Ala-Ser-Val-Ala) that can be recognized and phosphorylated on the serine residue by the bovine heart kinase. FPΔIL-11 therefore has the following sequence (upper nucleotide line in italic = human IL-11 joined CDS sequence SEQ ID NO:69, lower nucleotide line = FPΔIL-11 ; bottom amino acid line = FPΔIL-11 protein):

ATG AAC TGT GTT TGC CGC CTG GTC CTG GTC GTG CTG AGC CTG

15 *TGG CCA GAT ACA GCT GTC GCC CCT GGG CCA CCA CCT GGC CCC CCT*
ATG GAC TAC AAG GAT GAC GAT GAC AAG GAA GGT CGT CGT GCA TCT
 M D Y K D D D D K E G R R A S

20 *CGA GTT* *CTG TGA*
GTT GCA ...(idem hIL-11 joined CDS –SEQ ID NO:69- from position 32 to the end)... *CTG TGA*
V A L

The Flag tag of FPΔIL-11 is boxed ; the phosphorylation site recognized by the bovine heart protein kinase catalytic subunit created in FPΔIL-11 is underlined.

Hence, the nucleotide sequence of the non-mutated parental FPAIL-11 is the sequence of SEQ ID NO:77, and its amino acid sequence is the sequence of SEQ ID NO:78, shown on Figure 22.

5

And, the nucleotide sequence of FPAIL-11 mutated in accordance with the present invention is the sequence of SEQ ID NO:79, and the amino acid protein sequence of this mutated FPAIL-11 is the sequence of SEQ ID NO:80, shown on Figure 23.

- 10 Gel purified PCR fragments were ligated overnight at 16°C using T4 DNA ligase and then used to transform *E. coli* DH5 α . The corresponding plasmids were amplified in DH5 α , sequenced and then used to transform the BL21(DE3) strain of *E. coli*.

Production and purification of parental and mutant FPAIL-11

- 15 BL21 (DE3) cells transformed with the plasmid carrying the mutant or parental FPAIL-11 cDNA were cultured in Luria-Bertani medium containing 100 μ g/ml of ampicillin. Expression of the recombinant proteins was induced by 1mM IPTG for 2h at 37°C.

- E. coli* were then lysed by 30 minutes incubation at 37°C in presence of 0.1% triton X-100 and 150 μ g/ml of lysozyme in 50 mM Hepes, pH 7.4, followed by sonication for 5 minutes at an intensity level of 5 using a microprobe (Vibra Cell, Sonics Materials Inc. Danburg, Connecticut, USA). Lysates were centrifuged two times at 13,000 g for 25 min at 4°C and then assayed or purified as previously described [Wang *et al.* 2002, cited supra, and incorporated by reference]. Briefly, lysates were precipitated with 60% (NH₄)₂SO₄ in order to concentrate the crude proteins. Salts were eliminated by dialysis against 50 mM Hepes, pH 7.4 buffer before the purification of samples by chromatography on a Mono-S HR5/5 column (Amersham Pharmacia Biotech) using a 50 mM Hepes buffer, pH 7.4, and a 0-1 M NaCl gradient.
- 20
- 25

Quantification of parental and mutant FPΔIL-11 by ELISA

Two antibodies raised against human IL-11, a non-neutralising monoclonal antibody MAB618 and a biotinylated polyclonal BAF218, were used to quantify the recombinant human parental and muteins by sandwich ELISA method. 96-wells plates were coated
5 overnight at 4°C with 100 µl of monoclonal antibody MAB618 at a concentration of 2 µg/ml. After blocking with 3% BSA, 100 µl of serial dilution of samples were added and incubated for 1 hour at 37°C. After washing with PBST buffer (PBS buffer in the presence of 0.1% of Tween 20), plates incubated for another hour at 37°C with 100 µl/well of biotinylated polyclonal antibody BAF218 at a concentration of 30 ng/ml.
10 Before another incubation at 37°C for 1 hour with streptavidin conjugated alkaline phosphatase (1/5000), the plates were washed 3 times with TBS buffer (100 mM Tris-HCl, 150 mM NaCl, pH 7.5). Finally, the test was revealed using an ELISA Amplification System (Gibco BRL). Commercial recombinant IL-11 was used as a standard and the sensitivity was 2 pg/ml.

15 Mass Spectrometry

The exact molecular weight of the FPΔIL-11 and the mutein was determined using nano-electrospray mass spectrometry on a hybrid quadrupole Time-of-Flight Q-TOF mass spectrometer (Micromass, Whytenshaw, UK). Prior to analysis, samples were desalted using Vivaspin microconcentration devices with a cut-off of 10 kDa (Millipore,
20 Bedford, MA). After washing twice with water, samples were dissolved in a mixture of 50 % acetonitrile and 0.1 % formic acid in water to a concentration of approximately 5 pmol/µl. Four µl of this sample were loaded in a nano-electrospray capillary (MDS Proteomics, Odense, Dk) that was then placed in the special holder delivered with the instrument. Spray was initiated by slightly breaking the needle tip and supplementing a
25 small back-pressure of nitrogen. The capillary voltage was set at 1250 V. Spectra were accumulated for about 5 minutes, collecting data from m/Z 1000 to 2500 at 1 sec per scan. Data processing was performed using the Masslynx and MaxEnt software delivered with the instrument.

Infrared spectrometry

ATR-FTIR spectra were recorded at room temperature on a Bruker IFS55 FTIR spectrophotometer equipped with a liquid nitrogen-cooled mercury-cadmium-telluride (MCT) detector at a nominal resolution of 2 cm^{-1} and encoded every 1 cm^{-1} . The
5 internal reflection element (IRE) was a germanium plate ($50\times 20\times 2\text{ mm}$) with an aperture angle of 45° , yielding 25 internal reflections. The spectrophotometer was continuously purged with air dried on a FTIR purge gas generator 75-62 Balston (Maidstone, England) at a flow rate of 10-20 l/min in the sample compartment and 5 l/min in the optic compartment. Thin films were obtained by slowly evaporating a
10 sample under a stream of nitrogen on one side of the ATR plate [Fringeli and Gunthard (1981). *Infrared membrane spectroscopy*. Mol. Biol. Biochem. Biophys. 31, 270-332, the content of which is herein incorporated by reference]. The ATR plate was then sealed in a liquid sample holder. The sample on the ATR plate was rehydrated by flushing $^2\text{H}_2\text{O}$ -saturated N_2 , at room temperature. 256 scans were averaged for each
15 measurement. Secondary structure determination was based on the shape of the amide I band ($1600\text{--}1700\text{ cm}^{-1}$), which is sensitive to the secondary structure [Goormaghtigh *et al.* (1990). Secondary structure and dosage of soluble and membrane proteins by attenuated total reflection Fourier-transform infrared spectroscopy on hydrated films. Eur. J. Biochem. 193, 409-420, the content of which is herein incorporated by
20 reference].

Hydrogen/deuterium exchange kinetics: nitrogen was saturated with $^2\text{H}_2\text{O}$ by bubbling in a series of three vials containing $^2\text{H}_2\text{O}$. Before starting the deuteration, 10 spectra of the sample were recorded to test the stability of the measurements. At zero time, the $^2\text{H}_2\text{O}$ -saturated N_2 flux, at a flow rate of 100ml/min (controlled by a Brooks flow
25 meter), was connected to the sample. For each kinetic time point, 24 scans were recorded and averaged at a resolution of 4 cm^{-1} . All the spectra of the kinetics were corrected for atmospheric water absorption and side chain contribution. The subtraction of atmospheric water was done automatically by a home-written software which computed the subtraction coefficient as the ratio of the atmospheric water band between
30 1579 and 1572 cm^{-1} on the sample spectrum and on a reference atmospheric water spectrum [45-49]. The area of amide II, characteristic of the $\delta(\text{N-H})$ vibration, was

obtained by integration between 1596 and 1502 cm^{-1} . For each spectrum, the area of amide II was divided by the corresponding amide I $\nu(\text{C}=\text{O})$ area. This ratio expressed in percentage was plotted versus deuteration time. The 100% value is defined by the amide II/amide I ratio obtained before deuteration. The 0% value corresponds to a zero
5 absorption in the amide II region, observed for a full deuteration of the protein.

Circular dichroism

CD measurements were carried out on a Jasco J-720 spectropolarimeter (Japan Spectroscopic Co., Ltd., Tokyo, Japan) equipped with a temperature control unit and calibrated according to Chen and Yang [Chen and Yang (1977). Two-point calibration
10 of circular dichrometer with d-10-camphorsulfonic acid. Anal. Lett. 10, 1195-1207, the content of which is herein incorporated by reference]. The spectral bandwidth was 2 nm (< 250 nm) and 1 nm (> 250 nm), respectively. The measurements were carried out at a temperature of 20°C, the solvent was PBS throughout. The time constant ranged between 1 and 4 s and the cell path length between 0.1 and 10 mm.

15 Labelling of FPAIL-11 and of its mutein

FPAIL-11 and H/V-D/A were labelled through protein phosphorylation with [γ - ^{32}P]ATP in the presence of bovine heart kinase and phosphorylation was checked by autoradiography as previously described [Wang *et al.* (2002), cited *supra*, and incorporated by reference].

20 SDS-PAGE and Western blot

SDS-PAGE was carried out as previously described [Laemmli (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685, the content of which is herein incorporated by reference]. Muteins and parental FPAIL-11 were transferred from gels to a nitrocellulose membrane and detected
25 by incubation with biotinylated goat polyclonal antibody BAF218 (R&D), then streptavidin-conjugated alkaline phosphatase and finally revealed with the NBT/BCIP system (Sigma). Alternatively, proteins were detected using a biotinylated anti-flag antibody (M2 antibody, from Sigma).

Binding of ^{32}P -H/V-D/A to cells

Binding of ^{32}P -H/V-D/A on 7TD1 cells was carried out as described for the parental ^{32}P -FPΔIL-11 on B13Rα1 cells by Wang *et al* [Wang *et al.* (2002), cited *supra*, and incorporated by reference]. 7TD1 cells (5×10^5) were pre-incubated in culture medium
5 lacking growth factor for 2 h and were washed 3 times with phosphate-buffered saline, pH 7.4 (PBS). For binding studies, radiolabelled H/V-D/A was added to cells at the indicated concentration in PBS containing 0.5% bovine serum albumin. The mixture was incubated at 4 °C for the appropriate time and bound radiolabelled H/V-D/A was separated from the free radioactivity by centrifugation at 3000 g for 1 min through a 0.2
10 ml layer of a mixture of 40% dioctyl phthalate and 60% dibutyl phthalate (Janssen Chimica, Beerse, Belgium). After quick freezing, the tip of each tube containing the cell pellet was cut-off and radioactivity was counted in a Beckman β-counter. Non-specific binding was determined by incubating cells with radiolabelled H/V-D/A in the presence of a 200-fold molar excess of unlabelled H/V-D/A.

15 Surface plasmon resonance studies

These experiments were performed with a BiaCore 2000 optical biosensor (BiaCore, Uppsala, Sweden). A fusion protein of human IL-11R and IL-2 (IL-11R-IL-2) [Blanc *et al.* (2000). Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Rα) and their use in studies of human mononuclear cells. J. Immunol. Methods 241, 43-59, the content of which is herein incorporated by reference] was
20 coupled through primary amino groups to a carboxymethyl dextran flow cell (CM5) at a low immobilisation level (about 500 RU per flow cell) compatible with kinetic binding studies. Subsequent binding of parental FPΔIL-11 or mutein was carried out in Hepes-buffered saline (pH 7.4) at a flow rate of 10 μl/minute at room temperature.

25 IL-11 bioassay

IL-11 activity was measured using the 7TD1 cells. 2×10^3 cells/well were cultured in flat-bottom 96 wells microtiter plates during 7 days in the presence of serial dilutions of the purified mutein or parental FPΔIL-11, or *E. coli* crude lysates containing different muteins previously adjusted to the same protein concentration. The cell number in each

well was then determined by a colorimetric assay for hexosaminidase [Van Snick *et al.* (1986). Purification and NH₂-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cells hybridomas. Proc. Natl. Acad. Sci. U.S.A. 83, 9679-9683, the content of which is herein incorporated by reference].

- 5 Bioactivity was assayed similarly on 1×10^4 B9 cells/well for about 3 days and revealed by XTT colorimetric assay. Each sample was tested in triplicate using a commercial recombinant human IL-11 (from PeproTech) as a standard.

RESULTS

Expression, purification and initial characterisation of the H/V-D/A mutein

- 10 FPΔIL-11 was used as the human IL-11 parental molecule to generate IL-11 muteins by mutagenesis because i) it has the same biological activity as the wild-type human recombinant IL-11 and ii) the presence of the flag-tag (F), the phosphorylation site (P) and the absence of the first ten amino acids of IL-11 (Δ) allow a strong expression, a simple purification and an easy radio-labelling of IL-11 [Wang *et al.* (2002), cited
15 *supra*].

- To evaluate the involvement of H182 and D186 residues with respect to biological activity and receptor binding, the corresponding positions were substituted by site-directed mutagenesis using an inverse PCR method [Stemmer and Morris (1992), cited *supra*, and incorporated by reference]. These two residues were replaced by a valine
20 (H182/V) and an alanine (D186/A) to generate a mutein named H/V-D/A.

- The expression of these parental and mutant FPΔIL-11 in *E. coli* was analysed by SDS-PAGE (Figure 26). The parental molecule had an apparent molecular mass of about 24 kDa, a value higher than its theoretically expected one (20.050 kDa). This difference could be due to the introduction of numerous charged residues present in the
25 flag-tag and the phosphorylation site at the N-terminus of FPΔIL-11 (1 Glu, 5 Asp, 2 Arg and 2 Lys). Indeed, when the two charged residues H182 and D186 of FPΔIL-11 were replaced by two hydrophobic amino acids, the resulting mutein moved faster in gels than its parent, so that its apparent molecular mass (19 kDa) was close to its calculated one (19.9 kDa). This observation reinforced the hypothesis that the charged

residues could influence the molecular mobility in SDS-PAGE. However, to rule out the possibility that the reduced mobility of the H/V-D/A could be linked to a truncation of the protein, purified parental and mutant FPAIL-11 were submitted to mass spectrometric analysis. FPAIL-11 and H/V-D/A were found to have masses of 20.016 kDa and 19.934 kDa respectively, in perfect agreement with their predicted molecular masses.

Even though the increased electrophoretic mobility of the H/V-D/A mutein on SDS-PAGE is most likely due to charge modifications, we can not rule out the possibility that it would be partially due to a structural and/or conformational change of the molecule induced by mutagenesis. Such changes could render the mutein more compact than the parental molecule, therefore making it more resistant to heat denaturation and move faster in polyacrylamide gels.

Structural analysis by infrared spectrometry (IR) and circular dichroism (CD)

In order to further evaluate a potential conformational change induced by mutagenesis, the parent and mutant proteins purified to homogeneity were characterized by attenuated total reflection Fourier transform infrared spectrometry (ATR-FTIR). This technique has been successfully used to investigate the structure of soluble and membrane proteins [Goormaghtigh *et al.* (1990), cited *supra*]. The method is based on the analysis of the vibration bands of protein and particularly the amide I band, $\nu(\text{C=O})$, whose absorption frequency is dependent upon the secondary structure. Figure 27 represents the ATR-FTIR deuterated spectra of those two proteins recorded at pH 7.4. Their similar spectra suggest that the replacement of two amino acids (H182 and D186) by a valine and an alanine, respectively, does not have a detectable effect upon the protein secondary structure. The main absorption peak within the amide I is located in a region associated to the α -helical structure, confirming that this structure is predominant in both IL-11 (parent and mutein).

Parental and mutant IL-11 were also submitted to CD analysis because this technique is more sensitive to α -helical structures. Figure 28 shows their CD spectra. Both spectra have the same shape but their intensity is different. Secondary structure analysis [Kalai

et al. (1997). Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of action. Blood 89, 1319-1333, the content of which is herein incorporated by reference] of the far UV CD spectrum of both proteins reflect the α -helical character of the proteins (parental IL-11: α -helix 44.8
5 %, β -sheet 14.0%, turn 15%, remainder 26.2%; mutant IL-11: α -helix 38.8%, β -sheet 17.0%, turn 15.7%, remainder 28.5%), which are typical for a four-helix bundle cytokine. The somewhat lower helical content of the IL-11 mutein compared to the parental might reflect a conformational change introduced by the mutated amino acids.

To further characterize conformational changes taking place upon mutagenesis of
10 FPAIL-11, deuteration kinetics of the mutein and its parental protein were measured. In a soluble protein, the rate of hydrogen/deuterium exchange is essentially related to protein structure stability (local unfolding dynamics in secondary structures govern the exchange). The hydrogen exchange rate of the proteins was followed by monitoring the amide II absorbance peak decrease [$\delta(\text{N-H})$ maximum in the 1596-1502 cm^{-1} region]
15 because of its shift to the 1460 cm^{-1} region [amide II', $\delta(\text{N-D})$] upon deuteration (data not shown). The variations with time of the percentages of non-exchanged residues, calculated from the ratio of amide II/amide I as described in Experimental, are shown in Figure 29. It appears that the FPAIL-11 is undergoing a fast exchange, whereas H/V-D/A mutein is more resistant to hydrogen/deuterium exchange, suggesting that the
20 mutein might form oligomers and/or have a more compact structure than parental FPAIL-11.

By gel-filtration on a Superdex-75 column, parental and mutant proteins were both eluted at a similar position corresponding to a monomeric form (Figure 30), indicating that the increased hydrophobicity due to mutagenesis at site I did not lead to the
25 formation of dimers or oligomers.

Interaction with soluble IL-11R α

In order to find out if mutagenesis and associated conformational change of H/V-D/A have an effect on its interaction with IL-11R α , the association and dissociation kinetic constants (k_{on} , k_{off}) describing parent IL-11 and H/V-D/A mutein binding to human

IL-11R α were determined by surface plasmon resonance biosensor analysis using dextran-immobilized purified human IL-11R α -IL-2 [Blanc *et al.* (2000), cited *supra*] fusion protein as matrix. As depicted in Table 1 below, the association (k_{on}) and dissociation (k_{off}) kinetic constants of H/V-D/A were both much higher (35 and 14 fold respectively) than those of parental FPAIL-11, leading to an equilibrium dissociation constant (K_d) for the mutein that was 3-fold lower than for FPAIL-11.

Table 1: Kinetic (k_{on} association, k_{off} dissociation) and equilibrium (K_d dissociation) constants for the binding of FPAIL-11 and H/V-D/A to the recombinant human IL-11R-IL-2, determined by surface plasmon resonance.

IL-11	k_{on} ($M^{-1}s^{-1}$)	k_{off} (s^{-1})	K_d (nM)
FPAIL-11	$5.90 (\pm 0.90) \times 10^3$	$9.75 (\pm 0.05) \times 10^{-4}$	165 (± 25)
H/V-D/A	$2.30 (\pm 0.74) \times 10^5$	$1.34 (\pm 0.46) \times 10^{-2}$	58 (± 1.5)

If one translates the equilibrium dissociation constants in terms of free energies of interaction ($\Delta G = -RT \ln(1/K_D)$), binding of FPAIL-11 or H/V-D/A to IL-11R-IL-2 is accompanied by free energy changes of 9.2 or 9.8 kcal/mol, respectively, indicating that the mutagenesis and its induced conformational change favour IL-11 interaction with the IL-11R α receptor.

Interaction with cell surface IL-11 receptors

B13R α 1 and 7TD1 cells were used to test H/V-D/A binding to human and murine IL-11 receptors. B13R α 1 are Ba/F3 cells stably transfected with human gp130 and hIL-11R α [Lebeau *et al.* (1997). Reconstitution of two isoforms of the human interleukin-11 receptor and comparison of their functional properties. FEBS Lett. 407, 141-147, the content of which is herein incorporated by reference]. Non-specific binding component, determined by adding a 200-fold molar excess of unlabelled H/V-D/A, was low (less than 5% of the total association). Analysis of the specific binding data by the method of Scatchard indicated the existence of a single class of binding sites (see Table 2 below).

Table 2: Dissociation constants and numbers of sites per cell of FPΔIL-11 and H/V-D/A binding on B13Rα1 and 7TD1 cells

Ligands	B13Rα1		7TD1			
			Class 1 sites		Class 2 sites	
	K _d (nM)	Sites/cell	K _d (nM)	Sites/cell	K _d (nM)	Sites/cell
³²P-FPΔIL-11						
competed with FPΔIL-11	0.44	3079	7.20	391	0.65	16
competed with H/V-D/A	0.40	2900	ND*	ND	ND	ND
³²P-H/V-D/A						
competed with H/V-D/A	0.71	3462	2.70	486	0.60	16
competed with FPΔIL-11	0.72	3531	ND	ND	ND	ND
* ND: non determined						

5

We could only detect high affinity receptors on these cells probably because of an excess of gp130 expression on the surface of the transfected cells. The dissociation constant for the mutein ($K_d = 0.7$ nM) was higher than that for its parent ($K_d = 0.4$ nM). Binding of ³²P-H/V-D/A could be completely inhibited by an excess of FPΔIL-11 and the reverse was also found, showing that the two molecules compete with each other for this binding.

10

7TD1 is a murine hybridoma cell line resulting from the fusion of the mouse myeloma cell line Sp2/0-Ag14 with spleen cells from a C57BL/6 mouse. This cell line is well known to respond to picogram amounts of IL-6 [Van Snick *et al.* (1986), cited *supra*], but has also a proliferating response to nanogram amounts of IL-11 [Wang *et al.* (2002), cited *supra*].

15

When 7TD1 cells were used for ³²P-labelled H/V-D/A or FPΔIL-11 receptor binding assays, two classes of binding sites were observed (see the above Table 2): low affinity receptors with K_d in the nanomolar range likely corresponding to the binding of IL-11 or mutein to isolated IL-11Rα chains, and high affinity receptors with K_d in the picomolar range likely corresponding to the association of IL-11/IL-11Rα with gp130 transducing subunits. Similar numbers of either types of receptors were detected with

20

labelled FPΔIL-11 and H/V-D/A, in agreement with the above observation that the two molecules compete for common receptors. In the context of low affinity binding to isolated IL-11Rα chains, the affinity of H/V-D/A ($K_d = 2.7$ nM) was found to be around 3-fold higher than that determined for FPΔIL-11 ($K_d = 7.2$ nM), in agreement with the biosensor experiments (see the above Table 1). In the context of the high affinity receptor complex however, no differences were found between H/V-D/A and FPΔIL-11 binding ($K_d = 0.60$ nM vs 0.65 nM).

Induction of cell proliferation

To investigate to what extent the increased affinity of the mutein for the IL-11Rα could impact on its bioactivity, cell proliferation assays were conducted on different cell lines.

As shown in Figure 31A, H/V-D/A mutein, like IL-11, supports 7TD1 cell proliferation dose-dependently. However, the concentration of the mutein required to induce half-maximal proliferation (EC_{50}) was much lower (400-fold) than that required for the wild-type IL-11 ($EC_{50} = 0.03$ ng/ml for H/V-D/A vs 15 ng/ml for FPΔIL-11 and rhIL-11). This increased activity of the mutein was consistently found in several experiments, with a H/V-D/A/FPΔIL-11 activity ratio ranging from 60 to 400. Gel filtration experiments (Figures 30A and 30B) showed that parental and mutant IL-11 behaved as monomeric molecules (at about 20 kDa) with no sign of aggregation, and biological activity was fully associated with these monomers.

In sharp contrast to what was found on 7TD1 cells, the H/V-D/A mutein was about 10-fold less active on B9 cells (Figure 31B), another murine hybridoma cell line, indicating that the mode of action of the IL-11 mutein was more complex than expected.

In order to check if the H/V-D/A activity was mediated through gp130 transduction, we used an anti-IL-11 mAb (H2) that has been demonstrated to react with an epitope localized in site II of IL-11 [Blanc *et al.* (2000), cited *supra*]. By interfering with gp130 recruitment, this antibody inhibits the binding of FPΔIL-11 to its receptors and consequently inhibits IL-11-dependent cell proliferation [Wang *et al.* (2002), cited *supra*]. Figure 32 shows that this neutralizing antibody is able to inhibit 7TD1 cell proliferation induced by both the parental and mutant FPΔIL-11, indicating that the

- epitope recognized by the antibody H2 (site II) is conserved on H/V-D/A mutein, and that H/V-D/A, like parental IL-11, requires the gp130 subunit for exerting its bio-activity. The anti-human gp130 antibodies MAB628 and B-R3 did not affect parental or mutant IL-11 proliferation of the murine 7TD1 cells, and served as controls.
- 5 As far as these two antibodies have been shown to inhibit cell proliferation on human cells [Chevalier *et al.* (1996). Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. *J. Biol.Chem.* 271, 14764-14772], these results also indicate that the epitopes recognized by these antibodies on human gp130 are not shared by murine gp130.
- 10 When analysing the dose-response curves depicting the inhibitory effect of H2 antibody (Figure 32), it appeared that the concentration of H2 necessary to induce half-maximal inhibition (IC_{50}) was about 10 fold lower in the case of the H/V-D/A mutein than in the case of parental IL-11. This indicates that the H/V-D/A mutations at site I induce a conformational change at site II that results in an increased affinity for the H2 antibody.
- 15 Other experiments showed that H/V-D/A, like IL-11, was able to stimulate the proliferation of Ba/F3 cells co-transfected with human IL-11R α and human gp130, whereas Ba/F3 cells only transfected with human gp130 were insensitive to either molecule. Therefore H/V-D/A, like parental IL-11, cannot activate gp130 in the absence of IL-11R α .

20 **Relative roles of H182 and D186 in the properties of H/V-D/A**

- In order to investigate the relative importance of H182 and D186, these residues were mutated separately or in combination generating H/V, D/V, D/A and H/V-D/V muteins, in addition to H/V-D/A. As shown in Figure 33, SDS-PAGE and Western blot analysis indicate a good expression of all recombinant proteins. As observed before for
- 25 H/V-D/A, all muteins showed systematic differences between their apparent molecular mass on SDS-PAGE and their predicted one. Muteins D/V and D/A moved faster than the mutein H/V, suggesting that the negatively charged residue (D) had more impact on the molecular mobility in gels than the positively charged one (H). The difference of mobility between D/V and D/A also indicated that the charge is not the only factor
- 30 involved in the mobility change. This reinforces our previous hypothesis that beyond the charge, an SDS resistant conformational change of the molecules resulting from the

mutagenesis could also contribute to the mobility change. The two double muteins H/V-D/V and H/V-D/A had similar and higher mobilities than the single muteins, indicating cumulative effects of the two mutations.

7TD1 cells were used to measure the bioactivity of the various FPΔIL-11 muteins (Figure 34). It appeared that the D/A mutation alone resulted in a strong increase in activity, even stronger than the H/V-D/A combination. The D/V mutation also resulted in an increase in activity but to a far lower extent than the D/A mutation. In contrast, the H/V mutation always resulted in a slight reduction of bioactivity: H/V, H/V-D/V and H/V-D/A were less active than wild-type, D/V and D/A respectively.

These results suggest that D186 is a key amino acid in site I and plays an essential role in the activity of IL-11. Of note, replacement of D186 by a valine instead of an alanine resulted in a much lower increase of activity, suggesting that in addition to the hydrophobic nature, the size of the side chain at position 186 is crucial for this enhancement of activity. The H182 residue also appears to be involved in the interaction at site I but with a minor role.

DISCUSSION

The aim of this study was to create potent agonists of human IL-11 by changing amino acids located in the area (site I) responsible for binding to the specific receptor chain (IL-11R α). A model of IL-11 (Figure 25) was built by homology considerations based on the known receptor interaction sites of the related cytokines IL-6, CNTF, and LIF [Jacques *et al.* (1998). The interleukin-11/receptor complex: rational design of agonists/antagonists and immunoassays potentially useful in human therapy. Res. Immunol. 149, 737-740, the content of which is herein incorporated by reference]. Supported by mutagenesis experiments, the model predicts that the main energy for receptor ligand binding is provided by hydrophobic interactions of a few apolar side chains shielded by a surrounding scaffold of polar or charged residues which guarantee the specificity of the interaction by the formation of hydrogen bonds and salt bridges [Kalai *et al.* (1997), cited *supra*]. Therefore, in order to enhance the interaction of IL-11 with its α -receptor subunit, we replaced two charged amino acids residues H182 and D186 located in the middle of the site I hydrophobic cluster by two hydrophobic ones.

We anticipated that increasing locally the hydrophobicity on the surface of site I could influence the quaternary structure of the molecule: a putative large hydrophobic interaction zone generated by mutagenesis might favour H/V-D/A to form oligomers. Superdex-75 chromatography has evidenced that H/V-D/A is in fact expressed as a soluble functional monomeric protein. However, IR hydrogen/deuterium exchange kinetics showed that the H/V-D/A mutein is more resistant to $^1\text{H}/^2\text{H}$ exchange, suggesting that the mutein might have a more compact structure than parental FPΔIL-11. IR $^1\text{H}/^2\text{H}$ kinetic studies were indeed recorded at a higher protein concentration since the proteins were concentrated in a film for that experiment. It is then conceivable that additional interactions are present in the IR experiment. Yet, such local interactions encompassing the new, more hydrophobic, domain found in the H/V-D/A mutant could not explain the large effect reported on figure 29 where almost 40% of the residues experience a slower exchange, nor can such a difference be explained in view of the minor differences in the secondary structures. On the other hand, a more compact structure is deduced from the mutant's faster mobility on SDS-PAGE, in good agreement with the slower IR $^1\text{H}/^2\text{H}$ exchange and CD data.

Analysis of the binding characteristics of the H/V-D/A mutein confirmed that residues at the end of the D-helix are implicated in recognition for and interaction with IL-11R α . Indeed, biosensor studies showed that the H/V-D/A mutations were associated with modifications in the parameters of binding to the isolated IL-11R α chain. Both the association and dissociation constants were markedly increased, indicating that the nature of the molecular bonds involved in the cytokine-receptor interaction at site I were strongly modified. Despite these changes, the binding affinity of the mutein for IL-11R α was only three-fold higher than that of parental IL-11. Equilibrium studies on cell surface receptors confirmed this three-fold increase in affinity and further showed that in the context of the high affinity IL-11R α /gp130 complex, the mutein and wild type IL-11 displayed similar affinities.

The relative bioactivity of the H/V-D/A mutein as compared to wild type IL-11 was not correlated to the difference in affinity between the two molecules. Indeed, on the 7TD1 murine hybridoma cell line, the H/V-D/A had a considerably (up to 400-fold) increased activity, whereas on another murine hybridoma cell line (B9), its bioactivity was

reduced by about 10-fold. Such variations are in line with a previous study showing that, on another murine plasmocytoma cell line (T10), the substitution of the D186 by an alanine (D/A mutein) rendered the cytokine 500-fold less active than the wild-type [Czupryn *et al.* (1995), Ann. New York Acad. Sci. 762, 152-164, cited *supra* and herein
5 incorporated by reference].

What makes the H/V-D/A more active on 7TD1 cells? Since 7TD1 cells are highly responding to IL-6, such a high H/V-D/A bioactivity could result from their stimulation via IL-6R α -mediated signal transduction. As parental FP Δ IL-11 was found in this study to fully compete with ³²P-labelled H/V-D/A for its high affinity binding to 7TD1 cells
10 and since the binding of this radio-labelled protein to IL-6R α was not detectable in a RIA assay, this hypothesis can be refuted. The induction by H/V-D/A of murine IL-6 can be also excluded since we found that H/V-D/A bioactivity on 7TD1 was not modified in the presence of an IL-6 neutralising antibody. One has therefore to hypothesize that another factor, whose expression is cell line dependent, is responsible
15 for the enhanced activity of the H/V-D/A mutein. Such a factor could be another unknown receptor chain participating to the structure of the functional IL-11 receptors. The stoichiometry of IL-11 ligand-receptor complex is still an open question and a transducing subunit different from gp130 might participate in IL-11 mediated signal transduction. A possible candidate for this unknown subunit is the gp130-like receptor
20 (GLM-R) that has been recently identified and found to be expressed predominantly on activated monocytes [Ghilardi *et al.* (2002). A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J. Biol. Chem. 277, 16831-16836, the content of which is herein incorporated by reference]. This receptor is able to transduce a proliferation signal and induce activation
25 of the transcription factors STAT-3 and STAT-5. Even though its ligand has not yet been identified, GLM-R was not found to be «per se» a receptor for IL-11.

In the frame of such a hypothesis (heterocomplex of gp130 with gp130-like receptor), one could postulate that the conformational change induced by mutagenesis could render the mutein H/V-D/A more prone than wild type IL-11 to recruit and/or activate
30 this unknown gp130-like factor. As far as our studies on 7TD1 cells showed that H/V-D/A and wild type IL-11 displayed similar high affinity binding, the higher activity of

- H/V-D/A would be related to a higher signal transduction efficiency. Therefore, on cells that would express gp130-like in excess to gp130 (like 7TD1), the mutein would be more active, and conversely on cells (like B9 or T10) that would express gp130 in excess to gp130-like the mutein would be less active. Neutralizing antibodies inhibition experiments showed that site II of H/V-D/A remained functional, although its conformation was modified with respect to antibody H2 binding. Such a modification at site II could lead to the recruitment by H/V-D/A of a gp130-like molecule instead of gp130. Alternatively, site II of H/V-D/A would still be involved in recruitment of gp130 and site III involved in recruitment of gp130-like.
- 10 In conclusion, we have generated novel hIL-11 muteins with enhanced affinity for IL-11R α and strongly enhanced activity on 7TD1 cells. These muteins therefore constitute agonist molecules potentially useful in pathologies in which IL-11 has been shown to be beneficial. In addition, it should be a valuable molecule in further studies aiming at precisising the structure and function of the IL-11 receptors.

15

EXAMPLE 2: *in vivo* radioprotection.

- Mice.** C₅₇Bl/6 male mice, 8-12 weeks old, were purchased from Charles River Laboratories (Chatillon sur Chalaronne, France). Mice were housed at the animal core facility of INSERM U463 at Nantes (France). This facility is approved by the Préfecture of the French Department of Loire-Atlantique and is maintained in accordance with the regulations and standards of French Veterinary Services.

- Radiation and IL-11 treatment.** Whole body irradiation was delivered with a Teratron 780 (Atomic Energy of Canada limited, Canada) operating ⁶⁰Co sources. The dose rate was 1.5 Gy/min. Human recombinant FPA Δ IL-11 and H/V-D/A proteins (synthesized by Jean Content (Institut Pasteur, Bruxelles, Belgium) was solubilized in sterile PBS containing 0.2% gelatin, and delivered intravenously by retro-orbital injection of 800 ng, 30 minutes before irradiation and 5, 60 and 120 minutes after irradiation.

- Survival studies.** Survival as an end point was calculated from the time of treatment until death using the product limit Kaplan-Meier. Differences in product limit Kaplan Meier survival curves were evaluated by the Mantel log-rank test for censored data. Statistical analysis was performed by Student's t test.

Results

One of the major problems encountered by radiotherapists upon irradiation of patients' abdomen is the great radio-sensitivity of the gastrointestinal tract. Local irradiation of the abdomen leads to destruction of the intestinal villae, resulting in dehydration, septic shock and subsequently death of patient. This pathology is known as gastrointestinal syndrome (GI syndrome). It has long been established that death of the stem cells located in the intestinal crypts prevents the regeneration of epithelial cells causing necrosis of the villae (Potten CS, Merritt A, Hickman J, Hall P, Faranda A: Characterization of radiation-induced apoptosis in the small intestine and its biological implications. *Int. J. Radiat. Biol.* 65:71-8. 1994).

In mice, we observed that a single dose of 15 Gy induced total destruction of the intestinal mucosa and subsequent death of the animal (Paris F, Fuks Z, Kang A, Capodiec P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. *Science.* 293:293-7., 2001).

We therefore evaluated the therapeutic potential of FPΔIL-11 (described in the above example 1) in lethally irradiated C57BL6/J mice exposed to γ -rays, and found that FPΔIL-11 delays the death of the animals (median death 8 days for the mice pretreated by the FPΔIL-11 and irradiated versus 5 days for the mice vehicle treated and irradiated at 15 Gy). Results are illustrated by Figure 21.

In the same experimental conditions, we have evaluated the therapeutic activity of the H/V-D/A mutated proteins. A pretreatment with a 10 time lower dose of H/V-D/A, as compared to the dose used for the FPΔIL-11 (total doses 0,32 μ g versus 3,2 μ g) delays the mortality to the same iso-effect (median death at 8 days). Results are illustrated by Figure 22. Pretreatment with FPΔIL-11 at this low dose (0,32 μ g) has only a little impact in survey of the animal irradiated at 15 Gy.

These experiments show that the H/V-D/A mutein of the invention provides with a gain of function, as compared to the wild type IL-11, and improved the protection of the small intestines after exposure to radiation.

EXAMPLE 3: comparative results [single point mutation vs. double point mutation]

Quantification of H/V-D/A hIL-11 muteins in the blood serum

5

H/V-D/A IL-11 muteins are injected retroorbitally into the mice 30 minutes prior, 5 minutes, 1 hour and 2 hours after irradiation at 15 Gy.

In a first step, we determine the quantity of H/V-D/A IL-11 that is present in the blood after retroorbital injection.

10 To that end, an ELISA immunoassay is designed to measure H/V-D/A IL-11 in the blood serum collected 30 minutes after injection of 800ng of the mutein.

96-well plates have been pre-coated with an anti-human IL-11 antibody (polyclonal goat IgG available from R&D Systems under reference AF-218-NA). Standards with recombinant H/V-D/A IL-11 muteins or blood serum are then added to the appropriate

15 microtiter plate wells and incubated.

After washing to remove unbound IL-11 and other components of the sample, anti-Flag antibody against the Flag tag of the H/V-D/A IL-11 muteins (M2, Sigma) and biotin-conjugated polyclonal antibody against the M2 antibody are added and incubated. IL-11, if present, binds to and become immobilized by the antibody pre-coated on the wells

20 and is then "sandwiched" by the biotin conjugate.

In order to quantitatively determine the amount of IL-11 present in the sample, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The enzyme substrate reaction terminated by the addition of a sulphuric acid solution and the colour change is measured spectrophotometrically at a wavelength of

25 450 nm.

By this ELISA immunoassay, we detect H/V-DA IL-11 in the serum at the molarity of 2.2 nM, which represent a concentration of 3.3ng H/V-D/A hIL-11 by ml of blood (the volume of blood in the mice is around 5ml; and we injected 800ng of H/V-D/A hIL-11 (or 160ng/ml of blood) into the mice).

30 Our data show that 30 minutes after injection, 2% of the muteins are circulating in the blood. The rest has undergone degradation or has bound to their cell receptors.

Effect of D/A muteins

Single point D/A mutation hIL-11 muteins have been produced in accordance with the teaching of Czupryn *et al.* 1995 (cited *supra*), and compared to wild type FPΔIL-11
5 proteins and to the double point H/V-D/A hIL-11 muteins of the invention:

- first *in vitro* by proliferation induction assay on 7TD1 cells, and
- secondly *in vivo* by studying small intestines radioprotection and death of the animals.

10 Proliferation assays are made by incubating 7TD1 cells at the concentration of 2×10^3 cells in flat bottom 90-well plate in presence of an increasing dose of wild type FPΔIL-11 or its muteins. After 7 days, the number of surviving cells was determined by colorimetric assay for hexosamidase.

We found that DA and H/V-D/A hIL-11 have comparable dose response to cell
15 proliferation, whereas wild type recombinant IL-11 is less active (*cf.* Figure 35).

Survival of the mice injected retroorbitally with D/A IL-11 muteins after irradiation at 15 Gy are analyzed and compared to survival of the mice injected with wild-type FPΔIL-11 and with the H/V-D/A muteins of the invention (*cf.* Figure 36).

20 Whole body irradiation on 8-12 week-old C₅₇Bl/6 male mice is delivered with a Teratron 780 (Atomic Energy of Canada limited, Canada) operating ⁶⁰Co sources. The dose rate is 1.5 Gy/min. Human recombinant FPΔIL-11, D/A and H/V-D/A muteins are solubilized in sterile PBS containing 0.2% gelatin, and delivered intravenously by retro-orbital injection of 800 ng, 30 minutes before irradiation and 5, 60 and 120 minutes
25 after irradiation.

Survival as an end point is calculated from the time of treatment until death using the product limit Kaplan-Meier. Differences in product limit Kaplan Meier survival curves are evaluated by the Mantel log-rank test for censored data. Statistical analysis is performed by Student's t test. In the same experimental conditions, we evaluated the
30 therapeutic activity of the H/V-D/A mutated proteins of the invention as compared to the D/A muteins.

We already demonstrated that a pretreatment with a 10-time lower dose of H/V-D/A, as compared to the dose used for the FPΔIL-11 (total doses 0,32 μg versus 3,2 μg), delays the mortality to the same iso-effect (median death at 8 days); *cf.* example 2 above.

5 In the same experimental conditions, the injection of 0,32 μg of H/V-D/A muteins delays the mortality of the mice, but not injection of the same dose of D/A muteins. Mice injected with 0,32 μg and irradiated at 15 Gy died quickly with the same iso-effect than mice injected with the same low dose of wild type FPΔIL-11 and irradiated at the same dose.

10 These experiments show that if the H/V-D/A mutein of the invention provides with a gain of function, as compared to the wild type IL-11 and improved the protection of the small intestines after exposure to radiation, D/A mutein does not provide the same therapeutic gain.

CLAIMS

1. Method to produce an IL-11 agonist, which comprises producing a protein having the sequence of an IL-11 mutein that is derivable from a wild-type IL-11 sequence by replacement of at least two non-hydrophobic amino acids within the epitope for IL-11R α by hydrophobic ones.
2. IL-11 mutein, the sequence of which comprises a sequence which is derivable from the complete sequence of a wild-type IL-11:
- 10 - by replacement of the hydrophilic amino acids at positions 182 and 186 (positions computed by reference to the complete wild-type sequence) by X₁ and X₂ respectively, X₁ and X₂ being chosen from the group comprising:
- Valine (symbol = V or Val),
 - Alanine (symbol = A or Ala),
 - 15 ○ Proline (symbol = P or Pro),
 - Leucine (symbol = L or Leu),
 - Isoleucine (symbol = I or Ile),
 - Phenylalanine (symbol = F or Phe),
 - Methionine (symbol = M or Met), and
 - 20 ○ Tryptophan (symbol = W or Trp),
- and by deletion of a N-terminal portion that does not exceed the first 34 N-terminal amino acids.
3. IL-11 mutein of claim 2, characterized in that said wild-type IL-11 has the sequence of a human IL-11, or of a macaque IL-11, or of a mouse IL-11, or of a rat IL-11.
4. IL-11 mutein of claim 2 or 3, the sequence of which comprises a sequence chosen from the group comprising SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, SEQ ID NO:54, and the conservative variant sequences thereof, wherein said conservative variant sequences are of at least 80%, preferably at least 90% identity with at least one of SEQ ID NO:9, SEQ ID NO:24, SEQ ID NO:39, or SEQ ID NO:54, provided that X₁
- 30

and X₂ are still as defined in claim 2, and provided that the resulting variant protein has retained the ability to induce proliferation of an IL-11 dependent cell line.

5 5. IL-11 mutein according to any one of claims 2-4, characterized in that X₁ and X₂ are V or A.

6. IL-11 mutein according to any one of claims 2-5, characterized in that X₁=V and X₂=A.

10 7. IL-11 mutein of claim 6, characterized in that it comprises a sequence of SEQ ID NO:10, or of SEQ ID NO:25, or of SEQ ID NO:40, or of SEQ ID NO:55.

8. IL-11 mutein according to any one of claims 2-5, characterized in that X₁=A and X₂=V.

15

9. IL-11 mutein of claim 8, characterized in that it comprises a sequence of SEQ ID NO:11, of SEQ ID NO:26, of SEQ ID NO:41, or of SEQ ID NO:56.

20 10. IL-11 mutein according to any one of claims 2-5, characterized in that X₁=V and X₂=V.

11. IL-11 mutein of claim 10, characterized in that it comprises a sequence of SEQ ID NO:12, of SEQ ID NO:27, of SEQ ID NO:42, or of SEQ ID NO:57.

25 12. IL-11 mutein according to any one of claims 2-5, characterized in that X₁=A and X₂=A.

13. IL-11 mutein of claim 12, characterized in that it comprises a sequence of SEQ ID NO:13, of SEQ ID NO:28, of SEQ ID NO:43, or of SEQ ID NO:58.

30

14. IL-11 mutein according to any one of claims 2-13, characterized in that it comprises a sequence which is derivable from the complete sequence of a wild-type IL-11:

- by replacement of the hydrophilic amino acids in positions 182 and 186 (positions computed by reference to the complete wild-type sequence) by X_1 and X_2 respectively, X_1 and X_2 being as defined in claim 2, and

- by deletion of the first 21 N-terminal amino acids.

5

15. IL-11 mutein according to claim 14, characterized in that it comprises a sequence of SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:44 or SEQ ID NO:59, wherein X_1 and X_2 are defined in claim 2.

10 16. IL-11 mutein according to claim 15, characterized in that $X_1=V$ and $X_2=A$.

17. IL-11 mutein according to claim 16, characterized in that it comprises a sequence of SEQ ID NO:15, or of SEQ ID NO:30, or of SEQ ID NO:45, or of SEQ ID NO:60.

15 18. IL-11 mutein according to claim 15, characterized in that $X_1=A$ and $X_2=V$.

19. IL-11 mutein according to claim 16, characterized in that it comprises a sequence of SEQ ID NO:16, or of SEQ ID NO:31, or of SEQ ID NO:46, or of SEQ ID NO:61.

20 20. IL-11 mutein according to claim 15, characterized in that $X_1=V$ and $X_2=V$.

21. IL-11 mutein according to claim 20, characterized in that it comprises a sequence of SEQ ID NO:17, or of SEQ ID NO:32, or of SEQ ID NO:47, or of SEQ ID NO:62.

25 22. IL-11 mutein according to claim 15, characterized in that $X_1=A$ and $X_2=A$.

23. IL-11 mutein according to claim 22, characterized in that it comprises a sequence of SEQ ID NO:18, or of SEQ ID NO:33, or of SEQ ID NO:48, or of SEQ ID NO:63.

30 24. IL-11 mutein according to any one of claims 2-23, characterized in that it comprises a sequence which is derivable from the complete sequence of a wild-type IL-11, by replacement of the hydrophilic amino acids in positions 182 and 186 (positions

computed by reference to the complete wild-type sequence) by X_1 and X_2 respectively, X_1 and X_2 being as defined in claim 2.

25. IL-11 mutein according to claim 24, characterized in that it comprises a sequence of
5 SEQ ID NO:19, or of SEQ ID NO:34, or of SEQ ID NO:49, or of SEQ ID NO:64, wherein X_1 and X_2 are as defined in claim 2.

26. IL-11 mutein according to claim 24, characterized in that $X_1=V$ and $X_2=A$.

10 27. IL-11 mutein according to claim 26, characterized in that it comprises a sequence of SEQ ID NO:20, or of SEQ ID NO:35, or of SEQ ID NO:50, or of SEQ ID NO:65.

28. IL-11 mutein according to claim 24, characterized in that $X_1=A$ and $X_2=V$.

15 29. IL-11 mutein according to claim 28, characterized in that it comprises a sequence of SEQ ID NO:21, or of SEQ ID NO:36, or of SEQ ID NO:51, or of SEQ ID NO:66.

30. IL-11 mutein according to claim 24, characterized in that $X_1=V$ and $X_2=V$.

20 31. IL-11 mutein according to claim 30, characterized in that it comprises a sequence of SEQ ID NO:22, or of SEQ ID NO:37, or of SEQ ID NO:52, or of SEQ ID NO:67.

32. IL-11 mutein according to claim 24, characterized in that $X_1=A$ and $X_2=A$.

25 33. IL-11 mutein according to claim 32, characterized in that it comprises a sequence of SEQ ID NO:23, or of SEQ ID NO:38, or of SEQ ID NO:53, or of SEQ ID NO:68.

34. Nucleic acid, characterized in that its sequence codes for a mutein according to any one of claims 2-33.

30

35. Nucleic acid according to claim 34, characterized in that it comprises the sequence of SEQ ID NO:72, wherein each of $n_1n_2n_3$ and $n_4n_5n_6$ codes for:

- 5
- Valine (symbol = V or Val), or
 - Alanine (symbol = A or Ala), or
 - Proline (symbol = P or Pro), or
 - Leucine (symbol = L or Leu), or
 - Isoleucine (symbol = I or Ile), or
 - Phenylalanine (symbol = F or Phe), or
 - Methionine (symbol = M or Met), or
 - Tryptophan (symbol = W or Trp).
- 10 36. Nucleic acid according to any one claims 34-35, characterized in that it comprises the sequence of SEQ ID NO:72, wherein $n_1n_2n_3$ and $n_4n_5n_6$ are both selected from the group comprising the following codons:
- GCT, GCC, GCA, GCG,
 - GTT, GTC, GTA, GTG,
 - 15 - TTA, TTG, CTT, CTC, CTA, CTG,
 - ATT, ATC, ATA,
 - TTT, TTC,
 - ATG,
 - CCT, CCC, CCA, CCG,
 - 20 - TGG.
37. Nucleic acid according to any one of claims 34-36, characterized in that it comprises the sequence of SEQ ID NO:71 or of SEQ ID NO:70, wherein the codons $n_1n_2n_3$ and $n_4n_5n_6$ are as defined in any one of claims 35-36.
- 25 38. Nucleic acid according to any one of claims 34-36, characterized in that it comprises the sequence of SEQ ID NO:76 or of SEQ ID NO:74, wherein the codons $n_1n_2n_3$ and $n_4n_5n_6$ are as defined in any one of claims 35-36.
- 30 39. Nucleic acid according to any one claims 34-35, characterized in that it has the RNA sequence of SEQ ID NO:75, wherein the codons $n_1n_2n_3$ and $n_4n_5n_6$ are both selected from the group comprising the following codons:

- GCU, GCC, GCA, GCG
 - GUU, GUC, GUA, GUG,
 - UUA, UUG, CUU, CUC, CUA, CUG,
 - AUU, AUC, AUA,
 - 5 - UUU, UUC,
 - AUG,
 - CCU, CCC, CCA, CCG,
 - UGG.
- 10 40. Transfection vector, characterized in that it comprises a nucleic acid according to any one of claims 34-39.
41. Transfection vector according to claim 40, characterized in that it further comprises a nucleotide sequence coding for a Flag tag.
- 15 42. Transfection vector according to any one of claims 40-41, characterized in that it comprises the sequence of SEQ ID NO:79, wherein $n_1n_2n_3$ and $n_4n_5n_6$ are as defined in claim 35.
- 20 43. Cell, characterized in that it comprises a nucleic acid according to any one of claims 34-39, and/or which has been transfected by a transfection vector according to any one of claims 40-42, and/or which express a mutein according to any one of claims 2-33.
44. Drug characterized in that it comprises:
- 25 - a therapeutically effective amount of an IL-11 mutein according to any one of claims 2-33, or of a nucleic acid according to any one claims 34-39, or of a transfection vector according to any one of claims 40-42, or of a cell according to claim 43,
- and, optionally, a pharmaceutically-acceptable vehicle.
- 30 45. Drug according to claim 44, characterized in that it is intended for the prevention or treatment of an inflammatory disease or condition.

46. Drug according to any one claims 44-45, characterized in that it is intended for the prevention or treatment of a septic shock.

47. Drug according to any one claims 44-45, characterized in that it is intended for the
5 prevention or treatment of diabetes.

48. Drug according to any one claims 44-47, characterized in that it is intended for inhibiting microvascular endothelium apoptosis.

10 49. Drug according to claim 44, characterized in that it is an anti-thrombocytopenia drug.

1/48

<http://www.ncbi.nlm.nih.gov/entrez>

1: AY207429. Homo sapiens inte...[gi:27501935]

Links

LOCUS AY207429 9803 bp DNA linear PRI 05-JAN-2003

DEFINITION Homo sapiens interleukin 11 (IL11) gene, complete cds.

ACCESSION AY207429

VERSION AY207429.1 GI:27501935

KEYWORDS .

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 9803)

AUTHORS Rieder,M.J., Carrington,D.P., da Ponte,S.H., Hastings,N.C., Ahearn,M.O., Kuldane,S.A., Rajkumar,N., Toth,E.J., Yi,Q. and Nickerson,D.A.

TITLE Direct Submission

JOURNAL Submitted (26-DEC-2002) Genome Sciences, University of Washington, 1705 NE Pacific, Seattle, WA 98195, USA

COMMENT To cite this work please use: SeattleSNPs. NHLBI HL66682 Program for Genomic Applications, UW-FHCRC, Seattle, WA (URL: <http://pga.gs.washington.edu/>).

FEATURES Location/Qualifiers

source 1..9803
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

repeat region 1..278
/rpt_family="Alu"
/rpt_type=dispersed

variation 125
/frequency="0.01"
/replace="g"

variation 187
/frequency="0.01"
/replace="t"

repeat region 282..611
/rpt_family="Alu"
/rpt_type=dispersed

variation 357
/frequency="0.10"
/replace="c"

variation 447
/frequency="0.01"
/replace="c"

FIGURE 1

2/48

```

variation      509
                /frequency="0.09"
                /replace="c"
variation      970
                /frequency="0.01"
                /replace="c"
variation      970
                /frequency="0.44"
                /replace="a"
gene           1582..7566
                /gene="IL11"
mRNA           join(1582..1651,3014..3186,3386..3472,3584..3745,
                5778..7566)
                /gene="IL11"
                /product="interleukin 11"
CDS            join(1645..1651,3014..3186,3386..3472,3584..3745,
                5778..5948)
                /gene="IL11"
                /codon_start=1
                /product="interleukin 11"
                /protein_id="AA013493.1"
                /db_xref="GI:27501936"

      SEQ ID NO :1
/translation="MNCVCRLVLVVLSSLWPDTAVAPGPPPGPPRVSPDPRAELDSTVL
LTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLL
SYLRHVQWLRRAAGSSSLKTEPELGTQLARLDRLRLRLQLMSRLALPQPPDPPAPP .
LAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLKTRL"
variation      1671
                /gene="IL11"
                /frequency="0.01"
                /replace="a"
misc feature    2109..2947
                /gene="IL11"
                /note="Region not scanned for variation"
variation      3451
                /gene="IL11"
                /frequency="0.30"
                /replace="a"
variation      3638
                /gene="IL11"
                /frequency="0.01"
                /replace="a"
variation      3651
                /gene="IL11"
                /frequency="0.01"
                /replace="a"
variation      3835
                /gene="IL11"
                /frequency="0.01"
                /replace="a"

```

FIGURE 1

3/48

<u>variation</u>	4064
	/gene="IL11"
	/frequency="0.04"
	/replace="g"
<u>repeat region</u>	4196..4511
	/rpt_family="Alu"
	/rpt_type=dispersed
<u>variation</u>	4267
	/gene="IL11"
	/frequency="0.38"
	/replace="t"
<u>variation</u>	4802
	/gene="IL11"
	/frequency="0.18"
	/replace="g"
<u>repeat region</u>	5003..5113
	/rpt_family="Alu"
	/rpt_type=dispersed
<u>variation</u>	5108
	/gene="IL11"
	/frequency="0.15"
	/replace="a"
<u>repeat region</u>	5116..5426
	/rpt_family="Alu"
	/rpt_type=dispersed
<u>variation</u>	5154
	/gene="IL11"
	/frequency="0.01"
	/replace="t"
<u>variation</u>	5157
	/gene="IL11"
	/frequency="0.23"
	/replace="a"
<u>variation</u>	5199
	/gene="IL11"
	/frequency="0.03"
	/replace="c"
<u>variation</u>	5288
	/gene="IL11"
	/frequency="0.41"
	/replace="c"
<u>variation</u>	5970
	/gene="IL11"
	/frequency="0.01"
	/replace="t"
<u>variation</u>	6068
	/gene="IL11"
	/frequency="0.01"
	/replace="a"
<u>variation</u>	6077
	/gene="IL11"
	/frequency="0.02"
	/replace="t"

FIGURE 1

4/48

<u>variation</u>	6092 /gene="IL11" /frequency="0.17" /replace="a"
<u>variation</u>	6212 /gene="IL11" /frequency="0.15" /replace="g"
<u>variation</u>	6448 /gene="IL11" /frequency="0.10" /replace="a"
<u>variation</u>	6494 /gene="IL11" /frequency="0.10" /replace="c"
<u>variation</u>	6576 /gene="IL11" /frequency="0.11" /replace="a"
<u>variation</u>	6591 /gene="IL11" /frequency="0.05" /replace="t"
<u>repeat region</u>	6592..6897 /rpt_family="Alu" /rpt_type=dispersed
<u>variation</u>	6656 /gene="IL11" /frequency="0.05" /replace="g"
<u>variation</u>	6669 /gene="IL11" /frequency="0.18" /replace="g"
<u>repeat region</u>	6984..7169 /rpt_family="L1" /rpt_type=dispersed
<u>variation</u>	7083 /gene="IL11" /frequency="0.17" /replace="a"
<u>variation</u>	7161 /gene="IL11" /frequency="0.07" /replace="a"
<u>repeat region</u>	7170..7298 /rpt_family="Alu" /rpt_type=dispersed
<u>variation</u>	7249 /gene="IL11" /frequency="0.33" /replace="c"
<u>repeat region</u>	7299..7523 /rpt_family="L1" /rpt_type=dispersed

FIGURE 1

5/48

<u>repeat region</u>	7700..7835
	/rpt_family="MIR"
	/rpt_type=dispersed
<u>variation</u>	7904
	/frequency="0.05"
	/replace="c"
<u>repeat region</u>	8108..8316
	/rpt_family="Alu"
	/rpt_type=dispersed
<u>variation</u>	8111
	/frequency="0.27"
	/replace="c"
<u>variation</u>	8288
	/frequency="0.07"
	/replace="a"
<u>variation</u>	8337
	/frequency="0.19"
	/replace="a"
<u>repeat region</u>	8449..8518
	/rpt_family="Alu"
	/rpt_type=dispersed
<u>variation</u>	8680
	/frequency="0.12"
	/replace="a"
<u>variation</u>	8703
	/frequency="0.03"
	/replace="t"
<u>variation</u>	8790
	/frequency="0.01"
	/replace="t"
<u>variation</u>	9153
	/frequency="0.02"
	/replace="a"
<u>variation</u>	9596
	/frequency="0.03"
	/replace="t"
<u>variation</u>	9670
	/frequency="0.02"
	/replace="a"
<u>variation</u>	9680
	/frequency="0.31"
	/replace="g"

FIGURE 1

6/48

SEQ ID NO:73:

BASE COUNT 2004 a 3117 c 2797 g 1885 t

ORIGIN

```

1 acacctgtat tcccaccact ttgggagggt gaggcgggag gatgacctga gctcaggagt
61 ttgagaccag cctgggcaac atggcaaaac cctatctcta ctaaaaatac aaaaaatagc
121 caggcatggt ggcggtgccc tgtaatccca gctactcagg aggctgaggc atgagaatca
181 cttgaacctg ggaggcggag gttacagtga gctgagatca caccactgca cccagocctg
241 ggtgacacag cgagactctg tctcaaaaaa accaaaaacg aggccaggca cggtagctca
301 cacctgtcat occagcactt tgggaggcog aggcaggcgg atcacgaagt caggagtctg
361 agaccagcct ggccaacatg gtaagacccc gtctctacta aaaatacaaa attagccggg
421 tgtggtggcg cacacctgta atcccagcta cttgggaggc tgaggcagga gaatcgcttg
481 aaccgggag gtggagggtg cagtgaactg agattgtgcc attgatcgcg ccattgcact
541 ccagcctggg tgacagagtg agactcagta ccaaaaaaca aacaaacaaa aaacaaacaa
601 aaaatgagaa aggccttttac tctctgcccc cattgctgag tccccaacat ctcagcgtct
661 ctgtctttct aatatctctg tctccccttt tetgtccctg gggcctctcc gtccctgtca
721 ctctgccccg tgtctctgtt tgctggtgct ctttcttcag ctgcggcatc ctctgtctca
781 gagtcttggt gtctctgttc ctttcccctc ggggtctccc tgggtctccc caagtcccctc
841 ctgctgtctt cctcccgtct tctgatctct gactcccaga acctctccct ctgtctccag
901 ggctgcccct ctgatecctt ttgcttctct ggtgtgtctc tctggctgcc tccatctctg
961 tggatctccg tctcccgtct tctgtctcag tctgtccttc actctgtgtg tgtgtgtgtg
1021 tgtctctctc tctctctctc cttccccttc actccctctt cctcctgcct ccacctctcc
1081 aggccccctg cttgtccctc cgtccggcct ttctctgcct ttccgtctct ctgcccctcc
1141 atctctctct gctagtccct gtccagccgg acccccaccc acagtccggc cccagcgctt
1201 gagcctgagt gtctgtctcc gcccggtggg gtggaggagg gggacgcaa tgacctcacc
1261 agccccctct cgaccacccc cccctttccc ttttcaactt ttccaacttt tccctccgtg
1321 cctcctccg agcgcgcgcg cgtgagccct gcaaggcagc cgctccgtct gaatggaaaa
1381 ggcaggcagg gaggtgagt caggatgtgt caggccgccc tcccctgcog cctgcccccc
1441 gcccgcgccg cccagcccc taaaaacccc cccaggcgtc cacactccct cactgcgcog
1501 gccctgctgc tcagggcaca tgccctccct ccccaggcgg cggcccgact gacctcggg
1561 gctccccggg cagcggacag ggaagggtta aaggcccccg gctccctgcc cctgcccctg
1621 gggaaacccc ggccctgtgg ggacatgaac tgtaagtgtg ttcatgggga ggggtggagg
1681 gacaggaggg caggaggagg agggaccac ggcgggggtg ggagcagacc ccgctgagtc
1741 gcacagagag ggaccgggag acaggcagcc ggggaggaga gcagcttcgg agacaggagg
1801 cggcgaggga gatgggcaga gagagacaca gacaggagcg gatggaggca gccaatcaga
1861 ggcgcgcgag gagggacggg ccagacaggg ccccgagagg gagcagagcg cggagaccga
1921 gcaggggcag ggacgcaggg actggtgccg ggaggagggt gacccccatc gaccagggcc
1981 ccaggaggcc cgcggggacc gggagactcc ctgggattcc ggagagagg ctccggaggg
2041 aaactgaggc agggctcccg gagagcggag caagccaggg agtagcgacc ccagccgggg
2101 ggaggagaga gactgggcgc ggggggaaag cggggagagc cgggcagatg cggccgacgg
2161 aggcgcggac agaccgacgg ctggcgggcc cggggggcgg gctgggggtg tgcgaggcgc
2221 gggcgggcgg ggagcgtga ttggctggcg ggtggccggg tggcgggggc ggccgggggtg
2281 ggctgcgggg agcagactcc ggacccccgc gccccccgcg ccccccgcg ccccccgcg
2341 cagctctccc gctcccgcg ccggccgggg cccatggctc tgccccctct cggccagggtg
2401 cgctgcggcc cgggcttctg ccgcccaccc ggcggggctc ctgggagggc gtctaagggg
2461 tctcccgtgg gagaggtecg tgtctcccgg gctccgtcct ggcttctggc tccctcccct
2521 gctcccagcc agctcgggct ccgcggccc ggggaggggg caggttctgg cctgtgcctc
2581 cccaccatg ccccgcccc ggcccagat tccggcgtcc gggggcgagc gggagacgcc
2641 cggcccgctc acccgcccc ggccgcgtct gctccgacgg gcggggcagc cagagccagg
2701 gagggagagg gaagcccgcc tggccctgcg acctgccgc gggcgttcca cctgggact
2761 taagacctcc agctccatcc tccctaaggc cgggagttca ggccccagac cctcctcccc
2821 gagaccagag agtccagacc ccaggccttc ctccctcaga cctaggagtc caggccccca
2881 gcctctctct cctcagaccc aggaggagtc cagaccccag ttccctctcc ctcagacccg
2941 ggagtccagg cccaggccct cctctctcag accggagtc cagcctgagc tctctgcctt
3001 atcctgcccc cagggtgtttg ccgcctggtc ctggtcgtgc tgagcctgtg gccagataca
3061 gctgtcgccc ctgggcccac acctggcccc cctogagttt ccccagaccc tcggggccgag
3121 ctggacagca ccgtgtcctt gaccgcgtct ctccctggcg acacgcggca gctggctgca
3181 cagctggtag gagagactgg gctggggcca gcacaggagt gagaggcaga gaggaacgga

```

FIGURE 1

7/48

```

3241 gaggagtctg cgggcagcca cttggagggg ttctgggctc tcaggtggca gagtgagggg
3301 ggggaagagt tgggggcctg gcgtggggga tggaggggag cccgaggctg ggcagggggc
3361 acctcacagc ttttttcctt gccagagggg caaattccca gctgacgggg accacaacct
3421 ggattccctg cccaccctgg ccatgagtg cggggcactg ggagctctac aggttaagggc
3481 aagggaagtg gctggggaca aggtgggagg caggcagtga agggggcggg gaggatgagg
3541 ggcactggtc ggggtgttctc tgatgtcccg gctctatccc cagctcccag gtgtgctgac
3601 aaggctgcga gcggaacctac tgtcctacct gcggcacgtg cagtggctgc gccgggcagg
3661 tggctcttcc ctgaagacct tggagcccga gctgggcacc ctgcaggccc gactggaccg
3721 gctgctgcgc cggctgcagc tcctgggtatg tcctggcccc aagacctgac accccagacc
3781 cccaccctg gcccctaaat cctgtggcct gactccttga agcctgagac cccagaccgg
3841 agtgcaacag ccccgctctg agacctgacc accctaacag cccgctctga gacctgaca
3901 ccgtaacagc cccgctctga gacctgacc ctaacagtcc tgctctgaga cctgacct
3961 cgagtcctaa gatcctgtgg cctgagacc ctgaggccct agaccccaa atcctgccc
4021 gaaacttcaa attctcacc aagacctga gactccatca tccatgacct caaagtcccc
4081 agatcccagc ccctaagacc caagacccca tcctgaagcc caaagccttg agaattcaaa
4141 tcctcacctc aagacttgga gacctgggcc ccatgacatt gaaaaccatg gacctggcca
4201 ggcgtggtgg ctacgcctg taatcccagc actttgggag gccgaggcaa gtggatcacc
4261 tgaggtcggg agttcaagac cagccagacc aacatggtga aacctgtct ctactaaaa
4321 tacaaaatta gccaggcgtg tgggtgcatg cctgtaatcc cagctacttg ggagctgag
4381 gcaggagaat cgcttgaacc tgggagcgg aggttgcaat ggcggagat cgcaccatta
4441 cactccagcc tgggcaacaa gagcaaaact cctctctct caaaaaaaaa aaaaaaaaaa
4501 aaaagaagga aaagaaaacc atggacctcc agacctgag accccaggcc ccagccctga
4561 gatcctgaca tcttaaagat cccaggccct aagatacaag accttgacct aaagccagcc
4621 ttgggaccct ggctgtacaa acccaagacc tcaggacct agaccccgag ccctgaggcc
4681 ctatgtctca ctcccaacat cgaaaacct gacacctcag atcctgagcc tgcgcctgta
4741 cgactccaag acctcactt ccaaagccag gcccaaagcc ctgagaccag aagacttcaa
4801 acctggttc ttgggcctaa ctccaaagac cctggatctc aaattccaac ttctagctct
4861 gagactccag ccctcaccce tgagtctctg aactgaacc cagagacccc atctctaaga
4921 cttcagcctt gagatccagg gctgacct agactcgagc ccacagacct cagatactgt
4981 ctgtaaaacc ccagctctgg tggggagcag tggctcactc ctgtaatccc aaggcagggg
5041 aggccaaaggc agaaggacct cttgaggcca tgagtttgag acagcctggg cagcatagca
5101 agactctgtt tcttaattat tattattatt attatttttt ggagacagag tctcgctctc
5161 tgttgccag gctagagtgc aatggtgcca ttctggcttg ctggaacctc cgcctcctgg
5221 gctcaagcga ttctcctgcc tcagcctcct gactagctgg gacttcaggt gcacactgcc
5281 acacccgat aatttttttg tatttttagta gacacagggt ttcaccgtgt tgcccaggct
5341 ggtcacaacac tcctgagctc aggccatccg cccgcctcgg cctcccaaag cgtgggata
5401 acaggcgtga tcccgcgcgc ctggcttctt aattgttcta acagcagcca caacaacaaa
5461 aaccagctc tgagattcca gcccggcgca ctctaacagt cccaggcccc atccctcacc
5521 tagaaccgag atgccagccc tgactccaca gacttcaccc ccaaccccca cactcagctc
5581 tgggaagccc tcctgactcc agcctccatt ttcggaaccc cacagcctga agagctcccg
5641 gcctaaacac ttacccccac gcgccacagt cccctgtga atatgcagcc ccgattcagc
5701 tgcagctcca cagcaccctt gccctgcacc cccgctgcac ccctacctg tgactcactt
5761 ctctcctctc cccacagatg tcccgcctgg cctgccccca gccacccccg gaccggccgg
5821 cgcccccgct ggccgcccc cctcagcctt gggggggcat cagggcggcc cagccatcc
5881 tgggggggct gcaoctgaca cttgactggg ccgtgagggg actgctgctg ctgaagactc
5941 ggctgtgacc cggggcccaa agccaccacc gtccttccaa agccgatctt tatttattta
6001 tttatttcag tactgggggc gaaacagcca ggtgatcccc ccgccattat ctccccctag
6061 ttagagacag tccttocgtg aggcctgggg ggcatctgtg ccttatttat acttatttat
6121 ttcaggagca ggggtgggag gcaggtggac tcctgggtcc ccgaggagga ggggactggg
6181 gtcccggtt cttgggtctc caagaagtct gtccacagac ttctgcctg gctcttcccc
6241 atctaggcct gggcaggaac atatattatt tatttaagca attacttttc atgttggggt
6301 ggggacggag gggaaagggg agcctggggt tttgtacaaa aatgtgagaa acctttgtga
6361 gacagagaac aggggaattaa atgtgtcata catatccact tgagggcgat ttgtctgaga
6421 gctggggctg gatgcttggg taactggggg agggcaggtg gaggggagac ctccattcag
6481 gtggaggtcc cgagtgggag gggcagcgac tgggagatgg gtccgtcacc cagacagctc
6541 tgtggaggca ggtctgagc cttgctgggg gcccgcact gcatagggcc gtttgtttgt

```

FIGURE 1

```

6601 tttttgagat ggagtctcgc tctgttgccct aggctggagt gcagtgagggc aatctaaggt
6661 cactgcaacc tccacctccc ggggttcaagc aattctcctg cctcagcctc ccgattagct
6721 gggatcacag gtgtgcacca ccatgccagc ctaattatctt atttcttttg ttttttagt
6781 agagacaggg tttcaacctg ttggccaggc tggtttcgaa ctctgacct caggtgatcc
6841 tcctgcctcg gctcccaaa gtgctgggat tacaggtgtg agccaccaca cctgacctat
6901 aggtcttcaa taaatattta atggaagggt ccacaagtca ccctgtgatc aacagtaccc
6961 gtatgggaca aagctgcaag gtcaagatgg ttcattatgg ctgtgttcac catagcaaac
7021 tggaaacaat ctagatatcc aacagtgagg gttaagcaac atggtgcac tgtggataga
7081 acgccacca gccgccggga gcagggactg tcattcaggg aggctaagga gagaggcttg
7141 cttgggatat agaaagatat cctgacattg gccaggcatg gtggctcagc cctgtaatcc
7201 tggcactttg ggaggacgaa gcgagtggat cactgaagtc caagagtttg agaccggcct
7261 gcgagacatg gcaaaaccct gtctcaaaaa agaaagaatg atgtcctgac atgaaacagc
7321 aggtacaaa accactgcac gctgtgatcc caattttgtg ttttctttc tatatatgga
7381 ttaaaacaaa aatcctaaag ggaataacgc caaatgttg acaatgactg tctccaggct
7441 aaaggagaga ggtgggattg tgggtgactt ttaatgtgta tgattgtctg tttttacag
7501 aatttctgcc atgactgtgt attttgcacg acacatttta aaaaataata acactatctt
7561 tagaataaca gaatatcagc ctccctcctc ccaaaaaata gccctcagga ggggacaaag
7621 ttgaccgctg attgagcctg tcagggctgt gcactaagtg tgggcttttt acttacacaa
7681 tcctcctgga ctcttgaaata cgcctgtttt tacaggcgag ggaactgaag tctcagacaa
7741 gcgagtggga ctctgttgca caaagtcaca cagctaggga gagggtgaag tgggattctg
7801 cgccgtgtct ggctcttttc caaagctctc tttgcaagtc ggtgttgagg aatcctcgcc
7861 acatgcacac acatgagata tggagaaaca ggttcagtaa ggatttggtg cttaccagg
7921 gcctagagaa ggttcaatgg cagagtaggg atgataattc aaatgcttta gttacttttc
7981 cttttacaat aaccoagaca gacttccagg ggccccgtgt cgtcactagt ttgagtctgg
8041 gggttgagggt gcccatcctg ggccccgagt tttgattcac ccatcatagc cctcaagact
8101 ccaggctggc tgggcgcggt ggctcacgcc tgtaatccca gcactttggg aggtgagggc
8161 ggggtgatca cttgaggtca ggagtcaag gccagcctga ccaacatgga gaaacctgt
8221 ctctactaaa aatacaatcc agctactcgg aaggctgagg caggagaatc gctcgaacct
8281 aggagacggg ggttgcggtg agccgagatc acatcacaaa cagcctagg cagtgcgggg
8341 cccagggcga ggctcagacc tgcctccaca gagctgtctg ggtgatcgtg cctcctcgt
8401 ggaggcaggg tttgagcctc cctggggggc cccgcactgc taaggctgtt tgtttttgcg
8461 atggagtctc gctctgttgc ctaggctgga gtgcagtgtg gcaatctaag ctactgcct
8521 gggcaacaag agtgaaattc catctcaaaa aacaaaaaac aaacaacaa acaaaaaact
8581 ccaggctgta tccttgaggg agaagggagc ccacagtccc cggagagttc ctggaagagg
8641 cccctgtgtg tcogatgagg tcacaaagcc cctccaccag aggtcctcc cccagacccc
8701 tgctgtccac cctggcaggg ccatggcgga gggccgagtc tccagcctg gggcatctcc
8761 acgctctgta acgctgagct ccaggcaccc gtgaagcccc acgggtcaag gctggtgggc
8821 cggggctggg aggcctgcac gcctgggttc tgggtcccta aaccagtacc catccaccac
8881 agccaccatg atctggcttc gaaacaggag gtgccttgag ccgctccagg gcaccccga
8941 gtgggtccct gttctggggg agctgcaaaa gaccctccag aaggcgaggt acctgcccct
9001 ccgtccgctg cccatgttcg agagtaactt tgttcaggtc tccagtccc agtgccccgg
9061 ggctgagagg gacagagggg aagcaaggcc ccccgctgct ggggatcttg agagggaaag
9121 ggatttagca gtcactgtgt gggggacgat caggagggag gctcaggctg tggctgctgg
9181 aggaaggagt ggtcccagcc cctctccct ggctgcccc ggtgacccat caagggggcc
9241 cagtgttogt gaatcacaga accaacggc tggccatggg cgtggccgag tccctgcag
9301 gcctggtgtt gcctgacato ttgtgatcg gccagccgc cgaggacag cctgctccg
9361 gcctcgtgct gaccagggtc cgcaccccc aaccctcgg ccgccccct caccctcct
9421 gctctagacg ctccccctc cctctcccag gatgatccc ctggacctg tccacctctg
9481 cgtccatgac ctctctgcct ggcgcctgaa gctgcgcct gtctcgggc gccagtacta
9541 cctggccctg gacgcccctg acaacgaggt gggcttcctg ttccactgct ggggtccgct
9601 catcaacctg ctccaggagc cggctcccac ctggacccc aggaccacgc gcacggcccc
9661 cctggatatg ccgctggcca aagcgctgc ctccacctg cacctgcagg tgggatccca
9721 gctccacaga ccagggcagc gcaggcccca ggaacctcc ggcagatcc agaggggact
9781 cgaccaagag cccaaagtct agg

```

//

FIGURE 1

9/48

```

Complete native human IL-11 -SEQ ID NO:1-:
1      11      21      31      41      51
1 MNCVCRLVLV VLSLWPDVAV APGPPPGPPR VSPDPRAELD STVLLTRSLT ADTRQLAAQL      60
61 RDKFPADGDH NLDLPTLAM SAGALGALQL PGVLTRLRAD LLSYLRHVQW LRRAGGSSLK      120
121 TLEPELGTQ ARLDRLRLRL QLIMSRALP QPPDPPAPP LAPPSSAWGG IRAAHAILGG      180
181 LHLTLDWAVR GLLLLKTRL

Complete native macaque IL-11 (Macaca fascicularis) -SEQ ID NO:2- :
1      11      21      31      41      51
1 MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSLT EDTRQLTIQL      60
61 RDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAGGSSLK      120
121 TLEPELGTQ TRLDRLRLRL QLIMSRALP QLPPDPPAPP LAPPSSWTGG IRAAHAILGG      180
181 LHLTLDWAVR GLLLLKTRL

Complete native mouse IL-11 (Mus musculus) -SEQ ID NO:3- :
1      11      21      31      41      51
1 MNCVCRLVLV VLSLWPDVAV APGPPAGSPR VSSDPRADLD SAVLLTRSLT ADTRQLAAQM      60
61 RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK      120
121 TLEPELGTQ ARLERLLRL QLIMSRALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG      180
181 LHLTLDWAVR GLLLLKTRL

Complete native rat IL-11 (Rattus norvegicus) -SEQ ID NO:4- :
1      11      21      31      41      51
1 MNCVCRLVLV VLSLWPDVAV APGPPAGSPR VSSDPRADLD SAVLLTRSLT ADTRQLAAQM      60
61 RDKFPADGDH NLDLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK      120
121 TLEPELGTQ ARLERLLRL QLIMSRALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG      180
181 LHLTLDWAVR GLLLLKTRL

```

FIGURE 2

10/48

Native human IL-11 deleted from the 34 first aminoacids -SEQ ID NO :5-:

PRAELD STVLLTRSLL ADTRQLAAQL RDKFPADGDH NLDSLPTLAM
SAGALGALQL PGVLTRLRAD LLSYLRHVQW LRRAGGSSLK TLEPELGTQ
ARLDRLRLRL QLLMSRLALP QPPDPPAPP LAPPSSAWGG IRAAHAILGG
LHLTLDDWAVR GLLLLKTRL

Native macaque IL-11 deleted from the 34 first aminoacids -SEQ ID NO:6- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTQ
TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSWTGG IRAAHAILGG
LHLTLDDWAVR GLLLLKTRL

Native mouse IL-11 deleted from the 34 first aminoacids -SEQ ID NO:7- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
ARLERLLRLRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
LHLTLDDWAVR GLLLLKTRL

Native rat IL-11 deleted from the 34 first aminoacids -SEQ ID NO:8- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAGGPSLK TLEPELGALQ
ARLERLLRLRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
LHLTLDDWAVR GLLLLKTRL

FIGURE 3

11/48

hIL-11 mutein deriving from 34aa-deleted native human hIL-11 -SEQ ID NO :9-:

PRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDLPTLAMSAGALGA
 LQLPGVLTRLRADLLSYLRHVQWLRRAAGGSSLKTLEPELGTQARLDRLRLRL
 QLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLX₁LTLX₂WAVRGLL
 LKTRL wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

hIL-11 mutein deriving from 34aa-deleted native human hIL-11 -SEQ ID NO :10-:

PRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDLPTLAMSAGALGA
 LQLPGVLTRLRADLLSYLRHVQWLRRAAGGSSLKTLEPELGTQARLDRLRLRL
 QLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLVLT~~L~~A~~A~~WAVRGLLL
 LKTRL

hIL-11 mutein deriving from 34aa-deleted native human hIL-11 -SEQ ID NO :11-:

PRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDLPTLAMSAGALGA
 LQLPGVLTRLRADLLSYLRHVQWLRRAAGGSSLKTLEPELGTQARLDRLRLRL
 QLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGL~~A~~LTLY~~V~~WAVRGLLL
 LKTRL

hIL-11 mutein deriving from 34aa-deleted native human hIL-11 -SEQ ID NO :12-:

PRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDLPTLAMSAGALGA
 LQLPGVLTRLRADLLSYLRHVQWLRRAAGGSSLKTLEPELGTQARLDRLRLRL
 QLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLVLTLY~~V~~WAVRGLLL
 LKTRL

hIL-11 mutein deriving from 34aa-deleted native human hIL-11 -SEQ ID NO :13-:

PRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDLPTLAMSAGALGA
 LQLPGVLTRLRADLLSYLRHVQWLRRAAGGSSLKTLEPELGTQARLDRLRLRL
 QLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGL~~A~~LT~~L~~A~~A~~WAVRGLLL
 LKTRL

FIGURE 4

12/48

hIL-11 mutein deriving from 21aa-deleted native human hIL-11 -SEQ ID NO :14-:

PGPPPGPPRVSPDPRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDSL
 PTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSSLKTLEPELGT
 LQARLDRLRLRLQLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLX₁
 LTLX₂WAVRGLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

hIL-11 mutein deriving from 21aa-deleted native human hIL-11 -SEQ ID NO :15-:

PGPPPGPPRVSPDPRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDSL
 PTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSSLKTLEPELGT
 LQARLDRLRLRLQLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLYL
 TLAWAVRGLLLLKTRL

hIL-11 mutein deriving from 21aa-deleted native human hIL-11 -SEQ ID NO :16-:

PGPPPGPPRVSPDPRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDSL
 PTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSSLKTLEPELGT
 LQARLDRLRLRLQLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLAL
 TLVWAVRGLLLLKTRL

hIL-11 mutein deriving from 21aa-deleted native human hIL-11 -SEQ ID NO :17-:

PGPPPGPPRVSPDPRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDSL
 PTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSSLKTLEPELGT
 LQARLDRLRLRLQLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLYL
 TLVWAVRGLLLLKTRL

hIL-11 mutein deriving from 21aa-deleted native human hIL-11 -SEQ ID NO :18-:

PGPPPGPPRVSPDPRAELDSTVLLTRSLADTRQLAAQLRDKFPADGDHNLDSL
 PTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSSLKTLEPELGT
 LQARLDRLRLRLQLLMSRLALPQPPDPAPPLAPPSSAWGGIRAAHAILGGLAL
 TLAWAVRGLLLLKTRL

FIGURE 5

13/48

hIL-11 mutein deriving from complete native human hIL-11 -SEQ ID NO :19-:

MNCVCRLVLVVL^{SL}WPD^TAVAPGPPPGPPRVSPDPRAELDSTVLLTRSL^LADTR
 QLAAQLRDKFPADGDHNLD^{SL}PTLAMSAGALGALQLPGVLTRLRADLLSYLRH
 VQWLRRAGGSS^LKTLEPELGT^LQARLDRLRLRLQLLMSRLALPQPPDP^PPAPPL
 APPSSAWGGIRAAHAILGGL^{X₁}LT^L^{X₂}WAVRG^LLL^LLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

hIL-11 mutein deriving from complete native human hIL-11 -SEQ ID NO :20-:

MNCVCRLVLVVL^{SL}WPD^TAVAPGPPPGPPRVSPDPRAELDSTVLLTRSL^LADTR
 QLAAQLRDKFPADGDHNLD^{SL}PTLAMSAGALGALQLPGVLTRLRADLLSYLRH
 VQWLRRAGGSS^LKTLEPELGT^LQARLDRLRLRLQLLMSRLALPQPPDP^PPAPPL
 APPSSAWGGIRAAHAILGGL^VLT^L^AWAVRG^LLL^LLKTRL

hIL-11 mutein deriving from complete native human hIL-11 -SEQ ID NO :21-:

MNCVCRLVLVVL^{SL}WPD^TAVAPGPPPGPPRVSPDPRAELDSTVLLTRSL^LADTR
 QLAAQLRDKFPADGDHNLD^{SL}PTLAMSAGALGALQLPGVLTRLRADLLSYLRH
 VQWLRRAGGSS^LKTLEPELGT^LQARLDRLRLRLQLLMSRLALPQPPDP^PPAPPL
 APPSSAWGGIRAAHAILGGL^ALT^L^VWAVRG^LLL^LLKTRL

hIL-11 mutein deriving from complete native human hIL-11 -SEQ ID NO :22-:

MNCVCRLVLVVL^{SL}WPD^TAVAPGPPPGPPRVSPDPRAELDSTVLLTRSL^LADTR
 QLAAQLRDKFPADGDHNLD^{SL}PTLAMSAGALGALQLPGVLTRLRADLLSYLRH
 VQWLRRAGGSS^LKTLEPELGT^LQARLDRLRLRLQLLMSRLALPQPPDP^PPAPPL
 APPSSAWGGIRAAHAILGGL^VLT^L^VWAVRG^LLL^LLKTRL

hIL-11 mutein deriving from complete native human hIL-11 -SEQ ID NO :23-:

MNCVCRLVLVVL^{SL}WPD^TAVAPGPPPGPPRVSPDPRAELDSTVLLTRSL^LADTR
 QLAAQLRDKFPADGDHNLD^{SL}PTLAMSAGALGALQLPGVLTRLRADLLSYLRH
 VQWLRRAGGSS^LKTLEPELGT^LQARLDRLRLRLQLLMSRLALPQPPDP^PPAPPL
 APPSSAWGGIRAAHAILGGL^ALT^L^AWAVRG^LLL^LLKTRL

FIGURE 6

14/48

IL-11 mutein deriving from 34aa-deleted native macaque IL-11 -SEQ ID NO:24- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
 SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ
 TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSTWGG
 IRAAHAILGG L_{X₁}LT_{X₂}LWAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 34aa-deleted native macaque IL-11 -SEQ ID NO:25- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
 SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ
 TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSTWGG
 IRAAHAILGG L_YLT_LAWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native macaque IL-11 -SEQ ID NO:26- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
 SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ
 TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSTWGG
 IRAAHAILGG L_ALT_LYWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native macaque IL-11 -SEQ ID NO:27- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
 SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ
 TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSTWGG
 IRAAHAILGG L_YLT_LYWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native macaque IL-11 -SEQ ID NO:28- :

PRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH NLDSLPTLAM
 SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ
 TRLDRLRLRL QLLMSRLALP QLPPDPPAPP LAPPSSTWGG
 IRAAHAILGG L_ALT_LAWAVR GLLLLKTRL

FIGURE 7

15/48

IL-11 mutein deriving from 21aa-deleted native macaque IL-11 -SEQ ID NO:29- :

PGPPPGSPR ASPDPRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH
 NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK
 TLEPELGTQ TRLDRLRLRL QLLMSRLALP QLPPDPPAPP
 LAPPSSWGG IRAAHAILGG LX₁LTLY₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 21aa-deleted native macaque IL-11 -SEQ ID NO:30- :

PGPPPGSPR ASPDPRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH
 NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK
 TLEPELGTQ TRLDRLRLRL QLLMSRLALP QLPPDPPAPP
 LAPPSSWGG IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native macaque IL-11 -SEQ ID NO:31- :

PGPPPGSPR ASPDPRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH
 NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK
 TLEPELGTQ TRLDRLRLRL QLLMSRLALP QLPPDPPAPP
 LAPPSSWGG IRAAHAILGG LALTYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native macaque IL-11 -SEQ ID NO:32- :

PGPPPGSPR ASPDPRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH
 NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK
 TLEPELGTQ TRLDRLRLRL QLLMSRLALP QLPPDPPAPP
 LAPPSSWGG IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native macaque IL-11 -SEQ ID NO:33- :

PGPPPGSPR ASPDPRAELD STVLLTRSLL EDTRQLTIQL KDKFPADGDH
 NLDLPTLAM SAGALGALQL PSVLTRLRAD LLSYLRHVQW LRRAMGSSLK
 TLEPELGTQ TRLDRLRLRL QLLMSRLALP QLPPDPPAPP
 LAPPSSWGG IRAAHAILGG LALTYWAVR GLLLLKTRL

FIGURE 8

16/48

IL-11 mutein deriving from complete native macaque IL-11 -SEQ ID NO:34- :

MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSL
 EDTRQLTIQL KDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD
 LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ TRLDRLRLRL QLLMSRLALP
 QLPPDPPAPP LAPPSSTWGG IRAAHAILGG LX₁LTLY₂WAVR
 GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from complete native macaque IL-11 -SEQ ID NO:35- :

MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSL
 EDTRQLTIQL KDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD
 LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ TRLDRLRLRL QLLMSRLALP
 QLPPDPPAPP LAPPSSTWGG IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native macaque IL-11 -SEQ ID NO:36- :

MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSL
 EDTRQLTIQL KDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD
 LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ TRLDRLRLRL QLLMSRLALP
 QLPPDPPAPP LAPPSSTWGG IRAAHAILGG LALTYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native macaque IL-11 -SEQ ID NO:37- :

MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSL
 EDTRQLTIQL KDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD
 LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ TRLDRLRLRL QLLMSRLALP
 QLPPDPPAPP LAPPSSTWGG IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native macaque IL-11 -SEQ ID NO:38- :

MNCVCRLVLV VLSLWPDVAV APGPPPGSPR ASPDPRAELD STVLLTRSL
 EDTRQLTIQL KDKFPADGDH NLDLPTLAM SAGALGALQL PSVLTRLRAD
 LLSYLRHVQW LRRAMGSSLK TLEPELGTLQ TRLDRLRLRL QLLMSRLALP
 QLPPDPPAPP LAPPSSTWGG IRAAHAILGG LALTYWAVR GLLLLKTRL

FIGURE 9

17/48

IL-11 mutein deriving from 34aa-deleted native mouse IL-11 -SEQ ID NO:39- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
 LX₁LTLY₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 34aa-deleted native mouse IL-11 -SEQ ID NO:40- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
 LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native mouse IL-11 -SEQ ID NO:41- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
 LALTYWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native mouse IL-11 -SEQ ID NO:42- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
 LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native mouse IL-11 -SEQ ID NO:43- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH SLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS IRAAHAILGG
 LALTYWAVR GLLLLKTRL

FIGURE 10

18/48

IL-11 mutein deriving from 21aa-deleted native mouse IL-11 -SEQ ID NO:44- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS
 IRAAHAILGG LX₁LTLX₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 21aa-deleted native mouse IL-11 -SEQ ID NO:45- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS
 IRAAHAILGG LVLTLAWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native mouse IL-11 -SEQ ID NO:46- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS
 IRAAHAILGG LALTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native mouse IL-11 -SEQ ID NO:47- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS
 IRAAHAILGG LVLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native mouse IL-11 -SEQ ID NO:48- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYLRHVQW LRRAGGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPVIP LGPPASAWGS
 IRAAHAILGG LALTLAWAVR GLLLLKTRL

FIGURE 11

19/48

IL-11 mutein deriving from complete native mouse IL-11 -SEQ ID NO:49- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYLRHVQW LRRAGGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPVIP LGPPASAWGS IRAAHAILGG LX₁LTLX₂WAVR
 GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from complete native mouse IL-11 -SEQ ID NO:50- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYLRHVQW LRRAGGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPVIP LGPPASAWGS IRAAHAILGG LYLTLAWAVR GLLLLKTRL

IL-11 mutein deriving from complete native mouse IL-11 -SEQ ID NO:51- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYLRHVQW LRRAGGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPVIP LGPPASAWGS IRAAHAILGG LALTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native mouse IL-11 -SEQ ID NO:52- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYLRHVQW LRRAGGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPVIP LGPPASAWGS IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native mouse IL-11 -SEQ ID NO:53- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH SLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYLRHVQW LRRAGGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPVIP LGPPASAWGS IRAAHAILGG LALTLAWAVR
 GLLLLKTRL

FIGURE 12

20/48

IL-11 mutein deriving from 34aa-deleted native rat IL-11 -SEQ ID NO:54- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
 LX₁LT LX₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 34aa-deleted native rat IL-11 -SEQ ID NO:55- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
 LVLT LA WAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native rat IL-11 -SEQ ID NO:56- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
 LA LTY WAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native rat IL-11 -SEQ ID NO:57- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
 LVLT TY WAVR GLLLLKTRL

IL-11 mutein deriving from 34aa-deleted native rat IL-11 -SEQ ID NO:58- :

PRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH NLDSLPTLAM
 SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK TLEPELGALQ
 ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS IRAAHAILGG
 LA LTL A WAVR GLLLLKTRL

FIGURE 13

21/48

IL-11 mutein deriving from 21aa-deleted native rat IL-11 -SEQ ID NO:59- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS
 IRAAHAILGG LX₁LTLY₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from 21aa-deleted native rat IL-11 -SEQ ID NO:60- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS
 IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native rat IL-11 -SEQ ID NO:61- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS
 IRAAHAILGG L_ALTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native rat IL-11 -SEQ ID NO:62- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS
 IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from 21aa-deleted native rat IL-11 -SEQ ID NO:63- :

PGPPAGSPR VSSDPRADLD SAVLLTRSLL ADTRQLAAQM RDKFPADGDH
 NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD LMSYFRHVQW LRRAAGPSLK
 TLEPELGALQ ARLERLLRRL QLLMSRLALP QAAPDQPAVP LGPPASAWGS
 IRAAHAILGG L_ALTLYWAVR GLLLLKTRL

FIGURE 14

22/48

IL-11 mutein deriving from complete native rat IL-11 -SEQ ID NO:64- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYFRHVQW LRRAAGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPAVP LGPPASAWGS IRAAHAILGG LX₁LTLX₂WAVR GLLLLKTRL

wherein X₁ and X₂ are chosen from the group comprising :

- Alanine (A),
- Valine (V),
- Leucine (L),
- Isoleucine (I),
- Phenylalanine (F),
- Methionine (M),
- Proline (P),
- Tryptophan (W).

IL-11 mutein deriving from complete native rat IL-11 -SEQ ID NO:65- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYFRHVQW LRRAAGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPAVP LGPPASAWGS IRAAHAILGG LYLTLWAVR GLLLLKTRL

IL-11 mutein deriving from complete native rat IL-11 -SEQ ID NO:66- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYFRHVQW LRRAAGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPAVP LGPPASAWGS IRAAHAILGG LALTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native rat IL-11 -SEQ ID NO:67- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYFRHVQW LRRAAGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPAVP LGPPASAWGS IRAAHAILGG LYLTLYWAVR GLLLLKTRL

IL-11 mutein deriving from complete native rat IL-11 -SEQ ID NO:68- :

MNCVCRLVLV VLSLWPDRVV APGPPAGSPR VSSDPRADLD SAVLLTRSLL
 ADTRQLAAQM RDKFPADGDH NLDSLPTLAM SAGTLGSLQL PGVLTRLRVD
 LMSYFRHVQW LRRAAGPSLK TLEPELGALQ ARLERLLRRL QLLMSRLALP
 QAAPDQPAVP LGPPASAWGS IRAAHAILGG LALTLWAVR GLLLLKTRL

FIGURE 15

23/48

Joined CDS for human complete native IL-11 –SEQ ID NO:69–:

atg aac tgt gtt tgc cgc ctg gtc ctg gtc gtg ctg agc ctg tgg cca gat aca gct gtc gcc cct ggg cca cca
 cct ggc ccc cct cga gtt tcc cca gac cct cgg gcc gag ctg gac agc acc gtg ctc ctg acc cgc tct ctc
 ctg gcg gac acg cgg cag ctg gct gca cag ctg agg gac aaa ttc cca gct gac ggg gac cac aac ctg gat
 tcc ctg ccc acc ctg gcc atg agt gcg ggg gca ctg gga gct cta cag ctc cca ggt gtg ctg aca agg
 ctg cga gcg gac cta ctg tcc tac ctg cgg cac gtg cag tgg ctg cgc cgg gca ggt ggc tct tcc ctg aag
 acc ctg gag ccc gag ctg ggc acc ctg cag gcc cga ctg gac cgg ctg ctg cgc cgg ctg cag ctc ctg atg
 tcc cgc ctg gcc ctg ccc cag cca ccc ccg gac ccg ccg gcg ccc ccg ctg gcg ccc ccc tcc tca gcc tgg
 ggg ggc atc agg gcc gcc cac gcc atc ctg ggg ggg ctg cac ctg aca ctt gac tgg gcc gtg agg gga
 ctg ctg ctg ctg aag act cgg ctg tga

Joined CDS for the IL-11 mutein which derives from the 34aa-deleted human IL-11 –SEQ ID NO:70–:

cct cgg gcc gag ctg gac agc acc gtg ctc ctg acc cgc tct ctc ctg gcg gac acg cgg cag ctg gct gca
 cag ctg agg gac aaa ttc cca gct gac ggg gac cac aac ctg gat tcc ctg ccc acc ctg gcc atg agt gcg
 ggg gca ctg gga gct cta cag ctc cca ggt gtg ctg aca agg ctg cga gcg gac cta ctg tcc tac ctg cgg
 cac gtg cag tgg ctg cgc cgg gca ggt ggc tct tcc ctg aag acc ctg gag ccc gag ctg ggc acc ctg cag
 gcc cga ctg gac cgg ctg ctg cgc cgg ctg cag ctc ctg atg tcc cgc ctg gcc ctg ccc cag cca ccc ccg
 gac ccg ccg gcg ccc ccg ctg gcg ccc ccc tcc tca gcc tgg ggg ggc atc agg gcc gcc cac gcc atc
 ctg ggg ggg ctg n₁n₂n₃ ctg aca ctt n₄n₅n₆ tgg gcc gtg agg gga ctg ctg ctg ctg aag act cgg ctg
 tga

wherein the codon $n_1n_2n_3$ and the codon $n_4n_5n_6$ are both chosen among the group comprising the nucleotide codons which codes for a hydrophobic aminoacid, namely for Alanine (A), Valine (V), Leucine (L), Isoleucine (I), Phenylalanine (F), Methionine (M), Proline (P), Tryptophan (W).

$n_1n_2n_3$ and $n_4n_5n_6$ can be chosen among the group comprising the following nucleotide codons:

- GCT, GCC, GCA, GCG
- GTT, GTC, GTA, GTG,
- TTA, TTG, CTT, CTC, CTA, CTG,
- ATT, ATC, ATA,
- TTT, TTC,
- ATG,
- CCT, CCC, CCA, CCG,
- TGG.

FIGURE 16A

24/48

Joined CDS for the IL-11 mutein which derives from the 21aa-deleted human IL-11 – SEQ ID NO:71-:

cct ggg cca cca cct ggc ccc cct cga gtt tcc cca gac cct cgg gcc gag ctg gac agc acc gtg ctc ctg
acc cgc tct ctc ctg gcg gac acg cgg cag ctg gct gca cag ctg agg gac aaa ttc cca gct gac ggg gac
cac aac ctg gat tcc ctg ccc acc ctg gcc atg agt gcg ggg gca ctg gga gct cta cag ctc cca ggt gtg
ctg aca agg ctg cga gcg gac cta ctg tcc tac ctg cgg cac gtg cag tgg ctg cgc cgg gca ggt ggc
tct tcc ctg aag acc ctg gag ccc gag ctg ggc acc ctg cag gcc cga ctg gac cgg ctg ctg cgc cgg ctg
cag ctc ctg atg tcc cgc ctg gcc ctg ccc cag cca ccc ccg gac ccg ccg gcg ccc ccg ctg gcg ccc
ccc tcc tca gcc tgg ggg ggc atc agg gcc gcc cac gcc atc ctg ggg ggg ctg n₁n₂n₃ ctg aca ctt
n₄n₅n₆ tgg gcc gtg agg gga ctg ctg ctg ctg aag act cgg ctg tga

wherein the codon n₁n₂n₃ and the codon n₄n₅n₆ are as defined in Figure 16A.

Joined CDS for the IL-11 mutein which derives from the complete human IL-11 –SEQ ID NO:72-:

atg aac tgt gtt tgc cgc ctg gtc ctg gtc gtg ctg agc ctg tgg cca gat aca gct gtc gcc cct ggg cca cca
cct ggc ccc cct cga gtt tcc cca gac cct cgg gcc gag ctg gac agc acc gtg ctc ctg acc cgc tct ctc
ctg gcg gac acg cgg cag ctg gct gca cag ctg agg gac aaa ttc cca gct gac ggg gac cac aac ctg gat
tcc ctg ccc acc ctg gcc atg agt gcg ggg gca ctg gga gct cta cag ctc cca ggt gtg ctg aca agg
ctg cga gcg gac cta ctg tcc tac ctg cgg cac gtg cag tgg ctg cgc cgg gca ggt ggc tct tcc ctg aag
acc ctg gag ccc gag ctg ggc acc ctg cag gcc cga ctg gac cgg ctg ctg cgc cgg ctg cag ctc ctg atg
tcc cgc ctg gcc ctg ccc cag cca ccc ccg gac ccg ccg gcg ccc ccg ctg gcg ccc ccc tcc tca gcc tgg
ggg ggc atc agg gcc gcc cac gcc atc ctg ggg ggg ctg n₁n₂n₃ ctg aca ctt n₄n₅n₆ tgg gcc gtg agg
gga ctg ctg ctg ctg aag act cgg ctg tga

wherein the codon n₁n₂n₃ and the codon n₄n₅n₆ are as defined in Figure 16A.

FIGURE 16B

25/48

Mutated AY207429 nucleic acid -SEQ ID NO:74-:

```

1  acacctgtat  toccaccact  ttgggaggct  gaggcgggag  gatgacctga  gotcaggagt
61  ttgagaccag  cctgggcaac  atggcaaaac  cctatctcta  ctaaaaatac  aaaaaatagc
121  caggcatggt  ggcggtgccc  tgtaatccca  gctactcagg  aggtcagggc  atgagaatca
181  cttgaacctg  ggaggcggag  gttacagtga  gctgagatca  caccactgca  cccagcctg
241  ggtgacacag  cgagactctg  tctcaaaaaa  accaaaaaac  aggccaggca  cggtagctca
301  cacctgtcat  ccagcactt  tgggaggccg  aggcaggcgg  atcacgaagt  caggagtctg
361  agaccagcct  ggccaacatg  gtaagacccc  gtctctacta  aaaatacaaa  attagccggg
421  tgtggtggcg  cacacctgta  atcccagcta  cttgggaggc  tgaggcagga  gaatcgcttg
481  aaccggygag  gtggagggtg  cagtgaagct  agattgtgcc  attgatcgcg  ccattgcaact
541  ccagcctggg  tgacagagtg  agactcagta  ccaaaaaaca  aacaaacaaa  aaacaaacaa
601  aaaatgagaa  aggcctttac  tctctgcccc  cattgctgag  tccccaacat  ctcagcgtct
661  ctgtctttct  aatatctctg  tctccccttt  tctgtccctg  gggcctctcc  gtccctgtca
721  ctctgccccg  tgtctctggt  tgccctgtgc  ctttcttcag  ctgcggcact  ctctgtctca
781  gagtcttggt  gtctctgttc  ctttcccctc  ggggtctccc  tgggtctccc  caagtccctc
841  ctgtctgtct  cctcccgtct  tctgatctct  gactcccaga  acctctccct  ctgtctccag
901  ggctgcccc  ctgactctct  ttgcttctct  ggtgtgtctc  tctggctgcc  tccatctctg
961  tggatctccg  tctccctgtc  tctgtctcag  tctgtccttc  actctgtgtg  tgtgtgtgtg
1021  tgtctctctc  tctctctctc  cttcccttcc  actccctctt  cctcctgcct  ccacctctcc
1081  aggcctctgt  cttgtccctc  cgtccggcct  ttctctgcct  ttccgtctcc  ctgcctcccc
1141  atctctctct  gctagtccct  gtccagccgg  acccccaccc  acagtccggc  cccagcgctt
1201  gagcctgagt  gtctgtctcc  gccctggag  gtggaggagg  gggacgcaa  tgacctcacc
1261  agccctctc  cgaccacccc  cccctttccc  ttttcaactt  ttccaaactt  tccctccgtg
1321  ccctcctccg  agcgcgccgg  cgtgagccct  gcaaggcagc  cgctccgtct  cgaatggaaa
1381  ggcaggcagg  gaggtgagt  caggatgtgt  caggccgccc  tcccctgccc  cctgcccccc
1441  gcccgcgcc  cccagcccc  tatataaacc  cccaggcgct  cactctccct  cactgcccgc
1501  gccctgctgc  tcagggcaca  tgccctccct  cccaggcccg  cggcccagct  gaccctcggg
1561  gctcccccg  cagcggacag  ggaagggtta  aaggccccc  gctccctgcc  ccctgccctg
1621  gggaacccct  ggccctgtgg  ggacatgaac  tgtaagttag  ttcatgggga  ggggtggagg
1681  gacaggagg  caggaggagg  agggacccac  ggcgggggtg  ggagcagacc  ccgtctgagt
1741  gcacagagag  ggaccgcgg  acaggcagcc  ggggaggaga  gcagcttcgg  agacaggagg
1801  cggcgaggga  gatgggcaga  gagagacaca  gagaggagcg  gatggaggga  gccaatcaga
1861  ggcgcgcag  gagggacggg  ccagacaggg  ccccgagagg  gagcgagagc  cggagaccga
1921  ccaggggcag  ggaocgagg  actggtgccg  ggaggagggt  gaccccatc  gaccaggcc
1981  ccaggggacc  cgcggggacc  gggagactcc  ctgggattcc  ggagagagg  ctccggaggg
2041  aaactgagg  agggctccgc  gagagcggag  caagccagg  agtagcgacc  ccagccgggg
2101  ggaggagaga  gactgggcgc  ggggggaaag  cggggagagc  cgggcagatg  cggccgacgg
2161  aggcgcggac  agaccgacgg  ctggcgggcc  cggggggcgg  gctgggggtg  tgcgaggcgc
2221  gggcgcccg  ggagcgctga  ttggtctggc  ggtggccggg  tggcggggg  ggccgggggt
2281  ggctgcggg  agcgagctcc  ggacccccgc  gccccccgc  ccccccgcc  cccccgcgc
2341  cagctctccc  gctcccgcg  cccggccggg  cccatggctc  tgccctctc  cgccaggtg
2401  cgctgcggc  cgggcttctg  cggccacccc  ggcggggctc  ctgggagggc  gtctaagggg
2461  tctccgtgg  gagaggtccg  tgtctcccg  gctccgtcct  ggctctggc  tccctccct
2521  gctcccagcc  agctcggtct  cccgcggccc  ggggaggggg  caggttctgg  cctgtgcctc
2581  cccaccatg  cccgcgcccg  gggccagat  tccggcgctc  gggggcgga  gggagacgcc
2641  cggcccgct  accgcgcccg  ggcccgctct  gctccgacgg  gcggggcagc  cagagccagg
2701  gagggagagg  gaagcccgc  tggccctgcg  acctgcccgc  gggcggtcca  ccctgggact
2761  taagacctcc  agctccatcc  tccctaaggc  cgggagtcca  ggcccagac  cctcctcccc
2821  gagaccagg  agtccagacc  ccaggccttc  ctccctcaga  cctaggagtc  caggccccc
2881  gcctctcctc  cctcagaccc  aggaggagtc  cagaccccag  ttcctcctcc  ctccagcccg
2941  ggagtcagg  cccaggccct  cctctctcag  accggagtc  cagcctgagc  tctctgcctt
3001  atctgcccc  cagggtgttg  ccgctgtgtc  ctggctgtgc  tgagcctgtg  gccagatata
3061  cgtgtcgccc  ctgggcaacc  acctggcccc  cctcagagtt  cccagacccc  tcgggcccag
3121  ctggacagca  ccgtgtcctc  gaccgctct  ctctggcg  acacgcggca  gctggctgca
3181  cagctggtag  gagagactgg  gctggggcca  gcacaggagt  gagaggcaga  gaggaacgga

```

FIGURE 17

26/48

```

3241 gaggagtctg cgggcagcca cttggagggg ttctgggctc tcaggtggca gagtggggga
3301 ggggaagagt tgggggcctg gcgtggggga tggagggagc cccgaggctg ggcagggggc
3361 acctcacagc ttttttcctt gccagaggga caaattccca gctgacgggg accacaacct
3421 ggattccctg cccaccctgg ccatgagtgc gggggcactg ggagctctac aggtaagggc
3481 aaggagtggt gctggggaca aggtgggagg caggcagtga agggggcggg gaggatgagg
3541 ggcactgggtc ggggtgttctc tgatgtcccg gctctatccc cagctcccag gtgtgctgac
3601 aaggctgcga gcggacctac tgtcctacct gcggcacgtg cagtggctgc gccgggcagg
3661 tggctcttcc ctgaagacct tggagcccga gctgggcacc ctgcaggccc gactggaccg
3721 gctgctgcgc cggtgcagc tctgtgtatg tcctggcccc aagacctgac accccagacc
3781 cccaccctg gccccaaat cctgtggcct gagtccctga agcctgagac cccagaccg
3841 agtgcaacag cccgctctg agacctgac accctaacag cccgctctga gacctgaca
3901 ccgtaacagc cccgctctga gacctgacc ctaacagtcc tgctctgaga cctgacct
3961 gcagtcccaa gatcctgtgg ccctgagacc ctgaggccct agaccccaa atcctgccc
4021 gaaacttcaa attctacccc aagacctga gactccatca tccatgacct caaagtcccc
4081 agatcccagc ccctaagacc caagacccca tcctgaagcc caaagccttg agaattcaaa
4141 tcctcacctc aagacttggg gacctgggcc ccatgacatt gaaaaccatg gacctggcca
4201 ggcgtgggtg ctacgcctg taatcccagc actttgggag gccgaggcaa gtggatcaac
4261 tgaggtcggg agttcaagac cagccagacc aacatggtga aacctgtct ctactaaaaa
4321 tacaaaatta gccaggcgtg gtggtgcatg cctgtaatcc cagctacttg ggaggtgag
4381 gcaggagaat cgcttgaacc tgggaggcgg aggttgcatg gagccgagat cgcaccatta
4441 cactccagcc tgggcaacaa gagcaaaact ccctctctct caaaaaaaaaa aaaaaaaaaa
4501 aaaagaagga aaagaaaacc atggacctoc agacctgag accccaggcc ccagccctga
4561 gatcctgaca tcttaaagat cccaggccct aagatacaag accttgacct aaagccagcc
4621 ttgggacctt ggctgtacaa acccaagacc tccaggacct agaccccgag cctgagggcc
4681 ctatgtctca ctoccaacat cgaaaacctg gacacctcag atcctgagcc tgccgctgta
4741 cgactccaag acctcactt ccaaagccag gcccaaagcc ctgagaccag aagacttcaa
4801 acctgtgtt ttgggcctaa ctccaaagac cctggatctc aaattccaac ttctagctct
4861 gagactccag ccctcaccga tgagtctctg aacttgacc cagagacccc atctctaaga
4921 cttcagcctt gagatccagg gcctgacct agactcgagc ccacagacct cagatactgt
4981 ctgtaaaacc ccagctctgg tggggagcag tggctcactc ctgtaatccc aaggcagggg
5041 aggccaaagg agaaggacct cttgaggcca tgagtttgag acagcctggg cagcatagca
5101 agactctgtt tcttaattat tattattatt attatTTTTT ggagacagag tctcgcgctc
5161 tgttgcccag gctagagtgc aatggtgcca ttctggcctg ctggaacctc cgctcctgg
5221 gctcaagcga ttctcctgcc tcagcctcct gactagctgg gacttcaggt gcacactgcc
5281 acacccggt aattTTTTTg tatTTtagta gacacagggt ttcaccgtgt tgcccaggt
5341 ggtcacaaac tctgagctc aggcacatcc cccgctcgg cctcccaaag cgctgggata
5401 acaggcgtga tccgcgcgc ctggtctctt aattgttcta acagcagcca caacaacaaa
5461 aaccagctc tgagattcca gccccggoga ctctaacagt cccaggcccg atccctcacc
5521 tagaaccgag atgccagccc tgactccaca gacttcaccc ccaaccccca cactcagctc
5581 tggaagcccg tctgactcc agcctccatt ttcggaaccc cacagcctga agagctcccg
5641 gcctaaacac ttcaccccac gcgcacagat cccctgtga atatgcagcc ccgattcagc
5701 tgcagctcca cagcacccct gcctgcacc cccgctgcac cccctacctg tgactacct
5761 ctctcctctc cccacagatg tccgcctgg cctgccccca gccacccccc gacccgcccg
5821 cggccccgct ggcgcccccc tcctcagcct gggggggcat caggccgccc cagccatcc
5881 tgggggggct gn1gn2gn3ctgaca ctt1ct2ct3gtggg ccgtgagggg actgctgctg ctgaagactc
5941 ggctgtgacc cgggggccccaa agccaccacc gtccttccaa agccagatct tatttattta
6001 tttatttcag tactgggggc gaaacagcca ggtgatcccc ccgccattat ctccccctag
6061 ttagagacag tccttcogtg aggcctgggg ggcactctgt cctattttat acttatttat
6121 ttcaggagca ggggtgggag gcagggtggac tcctgggtcc ccgaggagga ggggactggg
6181 gtcccggatt cttgggtctc caagaagtct gtccacagac ttctgcccctg gctcttcccc
6241 atctaggcct gggcaggaac atatatattt tatttaagca attacttttc atgttgggg
6301 ggggacggag gggaaagggg agcctgggtt tttgtacaaa aactttgtga accctttgtg
6361 gacagagaac agggaaattaa atgtgtcata catatccact tgaggcgat ttgtctgaga
6421 gctggggctg gatgcttggg taactggggc agggcaggtg gaggggagac ctccattcag
6481 gtggagggtc cgagtgggcg gggcagcgac tgggagatgg gtcggtcacc cagacagctc
6541 tgtggaggca gggctctgac cttgcctggg gccccgact gcatagggcc gtttgtttgt

```

FIGURE 17

27/48

```

6601 tttttgagat ggagtctcgc tctgttgccct aggcctggagt gcagtgaggc aatctaagg
6661 cactgcaacc tccacctccc gggttcaagc aattctcctg cctcagcctc ccgattagct
6721 gggatcacag gtgtgcacca ccatgccagc ctaattatctt atttcttttg tatttttagt
6781 agagacaggg tttcaccatg ttggccaggc tggtttcgaa ctctgacct cagggtgatcc
6841 tcctgcctcg gcctcccaaa gtgctgggat tacagggtgtg agccaccaca cctgacctat
6901 aggtcttcaa taaatattta atggaagggt ccacaagtca ccctgtgatc aacagtaccc
6961 gtatgggaca aagctgcaag gtcaagatgg ttcatatagg ctgtgttcac catagcaaac
7021 tggaaacaat ctagatatcc aacagtagg gttaagcaac atggtgcac tgtggataga
7081 acgccacca gccgcccga gcagggactg tcattcaggg aggctaagga gagaggcttg
7141 cttgggatat agaaagatat cctgacattg gccaggcatg gtggctcacg cctgtaatcc
7201 tggcactttg ggaggacgaa gcgagtggat cactgaagtc caagagtttg agaccggcct
7261 gcgagacatg gcaaaaccct gtctcaaaaa agaaagaatg atgtcctgac atgaaacagc
7321 aggcacaaa accactgcat gctgtgatcc caattttgtg tttttcttcc tatatatgga
7381 ttaaaacaaa aatcctaaag ggaaatacgc caaatgttg acaatgactg tctccaggtc
7441 aaaggagaga ggtgggattg tgggtgactt ttaatgtgta tgattgtctg tattttacag
7501 aatttctgcc atgactgtgt attttgcctg acacatttta aaaataataa acactatttt
7561 tagaataaca gaatatcagc ctctcctctc ccaaaaataa gccctcagga ggggacaaag
7621 ttgaccgctg attgagcctg tcagggtgtg gcactaagtg tgggcttttt acttacacaa
7681 tcctcctgga ctcttgaata cgccctgttt tacaggcgag ggaaactgag tctcagacaa
7741 ggagtgggga ctctgttgca caaagtcaca cagctaggga gagtggaag tgggattctg
7801 cgccgtgtct ggctctttcc caaagctctc tttgcaagtc ggtgttgagg aatcctcgcc
7861 acatgcacac acatgagata tggagaaaca ggttcagtaa ggatttgggt cttaccaggg
7921 gcctagagaa gggtaaatg cagagtaggg atgataattc aaatgcttta gttacttttc
7981 cttttacaat aaccagaca gacttccagg gggcccgtgt cgtcactagt ttgactctgg
8041 ggttgagggt gcccatcctg ggcccgaggt tttgattcac ccatcatagc cctcaagact
8101 ccaggctggc tgggcgcggt ggctcacgcc tgaatccca gcactttggg aggcctgaggc
8161 ccgtggatca cttgaggtca ggagtcaag gccagcctga ccaacatgga gaaacctgt
8221 ctctactaaa aatacaatcc agctactcgg aaggctgagg caggagaatc gctcgaacct
8281 aggagacggg ggttgcggtg agccgagatc acatcacaaa cagccctagg cagtgcgggg
8341 cccagggcga ggctcagacc tgcctccaca gagctgtctg ggtgatcgtg cctcctccgt
8401 ggaggcaggg tttgagcctc cctggggggc ccgcactgc taaggctgtt tgtttttgcg
8461 atggagtctc gctctgttgc ctaggctgga gtgcagtgtg gcaatctaag ctactgcct
8521 gggcaacaag agtgaaattc catctcaaaa aacaaaaaac aaacaacaa acaaaaaact
8581 ccaggctgta tccctggagg agaaggagc ccacagtccc cggagagtc cgtgaagagg
8641 cccctgtgtg tcogatgagg tcacaaagcc cctccaccag aggcctctcc cccagcccc
8701 tgctgtccac cctggcaggg ccattggcga ggcccgagtc tcccagcctg gggcatctcc
8761 acgctctgta acgctgagct ccaggcaccc gtgaagcccc acgggtcaag gctggtgggc
8821 cggggctggg aggcctgcac gcctgggttc tgggtcccta aaccagtacc catccaccac
8881 agccaccatg atctggcttc gaaacaggag gtgccttgag ccgctccagg gcaccccga
8941 gtgggtccct gttctggggg agctgcaaaa gacctccag aaggcgaggt acctgccct
9001 ccgtccgctg cccatgttcc agagtaactt tgttcaggtc tccagttccc agtgccccgg
9061 ggctgagagg gacagagggg aagcaaggcc cccogtgctg ggggatcttg agagggaacg
9121 ggatttagca gtcactgtgt gggggacgat caggaggagg gctcaggctg tggctgtctg
9181 aggaaggagt ggtcccagcc cctctccctt ggtgccccca ggtgacctat caagggggcc
9241 cagtgttcgt gaatcacaga accaaccggc tggccatggg cgtggccgcc tccctgccag
9301 gccgtgtgtt gcctgacatc ttgctgatcg gccagccgcg cgaggacagg gactgctcgg
9361 gcctcgtgct gaccagggtg cgcatcccc aaccctcctg ccgccccctc caccctctct
9421 gctctagacg ctccccctc cctctcccag gatgatcccc ctggacctcg tccacctctg
9481 cgtccatgac ctctctgctt ggcgcctgaa gctgcgcctg gtctcgggcc gccagtacta
9541 cctggccctg gacgcccctg acaacgaggt gggcttcctg ttccactgct ggggtccgct
9601 catcaacctg cttcaggagc cggctcccac ctggaccccc aggaccacgc gcacggcccc
9661 cctggatatg ccgctggcca aagcgctgct ctcacacctg cactgacagg tgggatccca
9721 gctccacaga ccagggcagc gcaggcccca ggaacctcc ggccagatcc agaggggact
9781 cgaccaagag cccaaagtct agg

```

//

wherein the codon $n_1n_2n_3$ and the codon $n_4n_5n_6$ are as defined in Figure 16A.**FIGURE 17**

28/48

mRNA of IL-11 mutein deriving from human IL-11 -SEQ ID NO:75-:

gaa ggg uua aag gcc ccc ggc ucc cug ccc ccu gcc cug ggg aac ccc ugg ccc ugu ggg gac aug
 aac ugu guu ugc cgc cug guc cug guc gug cug agc cug ugg cca gau aca gcu guc gcc ccu ggg
 cca cca ccu ggc ccc ccu cga guu ucc cca gac ccu cgg gcc gag cug gac agc acc gug cuc cug acc
 cgc ucu cuc cug gcg gac acg cgg cag cug gcu gca cag cug agg gac aaa uuc cca gcu gac ggg
 gac cac aac cug gau ucc cug ccc acc cug gcc aug agu gcg ggg gca cug gga gcu cua cag cuc
 cca ggu gug cug aca agg cug cga gcg gac cua cug ucc uac cug cgg cac gug cag ugg cug cgc
 cgg gca ggu ggc ucu ucc cug aag acc cug gag ccc gag cug ggc acc cug cag gcc cga cug gac
 cgg cug cug cgc cgg cug cag cuc cug aug ucc cgc cug gcc cug ccc cag cca ccc ccg gac ccg ccg
 gcg ccc ccg cug gcg ccc ccc ucc uca gcc ugg ggg ggc auc agg gcc gcc cac gcc auc cug ggg
 ggg cug n1n2n3 cug aca cuu n4n5n6 ugg gcc gug agg gga cug cug cug cug aag acu cgg cug uga
 ccc ggg gcc caa agc cac cac cgu ccu ucc aaa gcc aga ucu uau uua uuu auu uau uuc agu acu
 ggg ggc gaa aca gcc agg uga ucc ccc cgc cau uau cuc ccc cua guu aga gac agu ccu ucc gug
 agg ccu ggg ggg cau cug ugc cuu auu uau acu uau uua uuu cag gag cag ggg ugg gag gca ggu
 gga cuc cug ggu ccc cga gga gga ggg gac ugg ggu ccc gga uuc uug ggu cuc caa gaa guc ugu
 cca cag acu ucu gcc cug gcu cuu ccc cau cua ggc cug ggc agg aac aua uau uau uua uuu aag
 caa uua cuu uuc aug uug ggg ugg gga cgg agg gga aag gga agc cug ggu uuu ugu aca aaa aug
 uga gaa acc uuu gug aga cag aga aca ggg aaU uaa aug ugu cau aca uau cca cuu gag ggc gau
 uug ucu gag agc ugg ggc ugg aug cuu ggg uaa cug ggg cag ggc agg ugg agg gga gac cuc cau
 uca ggu gga ggu ccc gag ugg gcg ggg cag cga cug gga gau ggg ucg guc acc cag aca gcu cug
 ugg agg cag ggu cug agc cuu gcc ugg ggc ccc gca cug cau agg gcc guu ugu uug uuu uuu gag
 aug gag ucu cgc ucu guu gcc uag gcu gga gug cag uga ggc aaU cua agg uca cug caa ccu cca
 ccu ccc ggg uuc aag caa uuc ucc ugc cuc agc cuc ccg auu agc ugg gau cac agg ugu gca cca
 cca ugc cca gcu aaU uau uua uuu cuu uug uau uuu uag uag aga cag ggu uuc acc aug uug gcc
 agg cug guu ucg aac ucc uga ccu cag gug auc cuc cug ccu cgg ccu ccc aaa gug cug gga uua
 cag gug uga gcc acc aca ccu gac cca uag guc uuc aaU aaa uau uua aug gaa ggu ucc aca agu cac
 ccu gug auc aac agu acc cgu aug gga caa gcu gca agg uca aga ugg uuc auu aug gcu gug uuc
 acc aua gca aac ugg aaa caa ucu aga uau cca aca gug agg guu aag caa cau ggu gca ucu gug

FIGURE 18

29/48

gau aga acg cca ccc agc cgc ccg gag cag gga cug uca uuc agg gag gcu aag gag aga ggc uug
 cuu ggg aua uag aaa gau auc cug aca uug gcc agg cau ggu ggc uca cgc cug uaa ucc ugg cac
 uuu ggg agg acg aag cga gug gau cac uga agu cca aga guu uga gac cgg ccu gcg aga cau ggc
 aaa acc cug ucu caa aaa aga aag aaU gau guc cug aca uga aac agc agg cua caa aac cac ugc aug
 cug uga ucc caa uuu ugu guu uuu cuu ucu aua uau gga uua aaa caa aaa ucc uaa agg gaa aua
 cgc caa aaU guu gac aaU gac ugu cuc cag guc aaa gga gag agg ugg gau ugu ggg uga cuu uua
 aug ugu aug auu guc ugu auu uua cag aaU uuc ugc cau gac ugu gua uuu ugc aug aca cau uuu
 aaa aaU aaU aaa cac uau uuu uag aaU

wherein the codon $n_1n_2n_3$ and the codon $n_4n_5n_6$ are both chosen among the group comprising the nucleotide codons which codes for a hydrophobic aminoacid, namely for Alanine (A), Valine (V), Leucine (L), Isoleucine (I), Phenylalanine (F), Methionine (M), Proline (P), Tryptophan (W).

$n_1n_2n_3$ and $n_4n_5n_6$ can be chosen among the group comprising the following nucleotide codons:

- GCU, GCC, GCA, GCG
- GUU, GUC, GUA, GUG,
- UUA, UUG, CUU, CUC, CUA, CUG,
- AUU, AUC, AUA,
- UUU, UUC,
- AUG,
- CCU, CCC, CCA, CCG,
- UGG.

FIGURE18

Gene of IL-11 muteins deriving from human IL-11 – SEQ ID NO:76-:

```

gaagggtta aaggccccg gctccctgcc cctgccttg
gggaacccct ggccctgtgg ggacatgaac tgtaagttgg ttcattgggga ggggtggaggg
gacagggagg cagggaggag agggaccac ggcgggggtg ggagcagacc ccgctgagtc
gcacagagag ggaccggag acaggcagcc ggggaggaga gcagcttcgg agacaggagg
cggcggaggga gatgggcaga gagagacaca gacaggagcg gatggaggca gccaatcaga
ggcgcgcgag gaggggacggg ccagacaggg ccccgagagg gagcgagacg cgggagaccga
gcaggggcag ggacgcaggg actggtgccg ggaggagggt gacccccatc gaccagggcc
ccaggagacc cgcggggacc gggagactcc ctgggattcc ggcagagagg ctccggaggg
aaactgaggc aggggtcccg gagagcggag caagccaggg agtagcgacc ccagccgggg
ggaggagaga gactgggcgc ggggggaaag cggggagagc cgggcagatg cggccgacgg
aggcgcggac agaccgacgg ctggcggggc cggggggcgg gctgggggtg tgcgaggcgc
gggcggccgg ggagcgctga ttgctggcg ggtggccggg tgggcggggg ggcgggggtg
ggctgcgggg agcgagctcc ggacccccgc gccccccgc cccccgcgc cccccgcgc
cagctctccc gctcccgcg cccggccggg cccatggctc tgccctctc cggccagggtg
cgctgcggcc cgggcttctg ccgcccaccc ggcggggctc ctgggagggg gtctaagggg
tctcccggtg gagaggtccg tgtctcccg gctccgtcct ggcttctggc tccctccct
gctcccagcc agctcgggct cccgcggccc ggggaggggg cagggttctg cctgtgcctc
ccccaccatg ccccgccccg gggccagat tccggcgctc gggggcggac ggggagaccg
cggcccgctc acccgccccg ggcgcgctc gctccgacgg gcggggcagc cagagccagg
gagggagagg gaagcccgcc tggccctgg acctgcccgc gggcggtcca cctgggact
taagaccctc agtccatcc tccctaaggc cgggagtcca ggcaccagac cctctcccc
gagaccagg agtccagacc ccaggccttc ctccctcaga cctaggagtc caggccccc
gcctctctc cctcagaccc aggaggagtc cagaccccag ttccctctc ctcagaccg
ggagtccagg cccaggccct cctctctcag acccgagtc cagcctgagc tctctgcctt
atcctgcccc cagggtgtttg ccgctggtc ctggtcgtg tgagcctgtg gccagatata
gctgtcggcc ctggggccacc acctggcccc cctcgagttt cccagaccc tcggggcgag
ctggacagca cgtgctcct gaccgctct ctctggcg acacgcggca gctggctgca
cagctggtag gagagactgg gctggggcca gcacaggagt gagaggcaga gaggaaacgga
gaggagtctg cgggcagcca ctggagggg ttctgggctc tcagggtggc gagtgaggga
ggggaagagt tgggggcctg gcgtggggga tggagggagc ccgaggctg ggcaggggcc
acctcacagc ttttttccct gccagaggga caaattocca gctgacgggg accacaacct
ggattccctg cccaacctgg ccatgagtc gggggcactg ggagctctac aggttaagggg
aagggagtg gctggggaca aggtggagg caggcagtga agggggcggg gaggatgagg
ggcactggtc ggggtgttct tgatgtccg gctctatcc cagctccag gtgtgctgac
aaggctgga gcgacactac tgtctacct gcggcacgt cagtggctgc gccgggcagg
tggtcttcc ctgaagacc tggagcccga gctgggcacc ctgcaggccc gaotggaccg
gctgctgcgc cggtgcagc tccgtgtatg tccggcccc aagacctgac accccagacc
cccacccctg gccccaaaat cctgtggcct gactcctga agcctgagac cccagaccg
agtgaacag cccgctctg agacctgac accctaacag cccgctctga gacctgaca
ccgtaacag cccgctctga gacctgacc ctaacagtc tgctctgaga cctgacct
gcagtcccaa gatcctgtg cctgagacc ctgaggccct agaccccaa atcctgccc
gaaacttcaa attctcacc aagacctga gactccatca tccatgacct caaagtcccc
agatcccagc ccctaagacc caagacccca tctgaagcc caaagcctg agaattcaaa
tctcacctc aagacttga gacctggcc ccatgacatt gaaaacctg gacctggcca
ggcgtgggtg ctcaogcctg taatcccagc actttgggag gccgaggcaa gtggatcacc
tgaggtcggg agttcaagac cagccagacc aacatggtga aacctgtct ctactaaaaa
tacaaaatta gccaggcgtg gtggtgcatg cctgtaatcc cagctacttg ggaggctgag
gcaggagaat cgcttgaacc tgggaggcgg aggttgagc gagccgagat cgcaccatta
cactccagcc tgggcaacaa gagcaaaact cctctctct caaaaaaaa aaaaaaaa
aaaagaagg aaagaaaacc atggacctc agacctgag accccaggcc ccagccctga
gatcctgaca tottaaagat cccaggccct aagatacaag acctgaccc aaagccagcc
ttgggacctt ggctgtacaa acccaagacc tocaggacct agaccocgag ccctgaggcc
ctatgtctca ctcccaacat cgaaaacct gacacctcag atcctgagcc tgcgcctgta
cgactccaag acctcactt ccaaagccag gcccaaagcc ctgagaccag aagacttcaa
acctgggtc ttgggcctaa ctccaaagac cctggatctc aaattccaac ttctagctct
gagactccag cctcaccaca tgagttcctg aacttgaacc cagagacccc atctctaaga
cttcagcctt gagatccagg gcctgacct agactogag ccacagacct cagatactgt

```

FIGURE 19

31/48

```

ctgtaaaacc ccagctctgg tggggagcag tggctcactc ctgtaatccc aaggcagggg
aggccaaggc agaaggacct cttgaggcca tgagtttgag acagcctggg cagcatagca
agactctggt tcttaattat tattattatt attatttttt ggagacagag tctcgcgctc
tgttgcccag gctagagtgc aatggtgcca tttcggcttg ctggaacctc cgctctctgg
gctcaagcga ttctcctgcc tcagcctcct gagtagctgg gacttcagggt gcacactgcc
acacccggat aatttttttt tatttttagta gacacagggt ttcacogtgt tgcccaggct
ggtcacaacac tcctgagctc agggcatcog cccgcctcgg cctcccaaag cgctgggata
acaggcgtga tcccgcgcgc ctggcttctt aattgttcta acagcagcca caacaacaaa
aaccagctc tgagattcca gccccggcga ctctaacagt cccaggcccc atccctcacc
tagaaccgag atgccagccc tgactccaca gacttcaccc ccaaccccc cactcagctc
tggaagcccg tcctgactcc agcctccatt ttcggaaccc cacagcctga agagctcccg
gcctaaacac ttcaccccac gcgccacagt ccccctgtga atatgcagcc cggattcagc
tgcaagctcca cagcaccctt gccctgcacc cccgctgcac cccctacctg tgactcacct
ctctcctctc cccacagatg tcccgcctgg cctgccccca gccacccccg gaccgcggg
cgcccccgct ggggcccccc tctcagcctt gggggggcat cagggccgcc cagccatcc
tgggggggct gn1n2n3ctgaca cttn4n5n6ggg cctgagggg actgctgctg ctgaagactc
ggctgtgacc cggggcccaa agccaccacc gtccttccaa agccagatct tatttattta
tttatttcag tactgggggc gaaacagcca ggtgatcccc ccgccattat cccccctag
ttagagacag tccttcctgt aggcctgggg ggcattctgt ccttatttat acttatttat
ttcaggagca ggggtgggag gcaggtggac tcctgggtcc ccgaggagga ggggactggg
gtcccggatt cttgggtctc caagaagtct gtccacagac ttctgccctg gctctcccc
atctaggcct gggcaggaac atataattat tatttaagca attacttttc atgttgggggt
ggggacggag gggaaaggga agcctgggtt tttgtacaaa aatgtgagaa acctttgtga
gacagagaac agggaattaa atgtgtcata catatccact tgaggcgat ttgtctgaga
gctggggctg gatgcttggg taactggggc agggcagggt gaggggagac ctccattcag
gtggaggctc cagtgggcg gggcagcgac tgggagatgg gtcggtcacc cagacagctc
tgtggaggca gggctctgagc cttgcctggg gccccgcact gcatagggoc gtttgtttgt
tttttgagat ggagtctcgc tctgttgctt aggcctggagt gcagtgggc aatctaagggt
cactgcaacc tcacacctcc gggttcaagc aattctcctg cctcagcctc ccgattagct
gggatcacag gtgtgcacca ccatgccag ctaattattt atttcttttg tatttttagt
agagacaggg tttcaccatg ttggccaggc tggtttcgaa ctccctgaact cagggtgatcc
tcctgcctcg gcctcccaa gtgctgggat tacagggtgt agccaccaca cctgacccat
aggtcttcaa taaatattta atggaagggt ccacaagtca ccctgtgatc aacagtaccc
gtatgggaca aagctgcaag gtcaagatgg ttcattatgg ctgtgttcac catagcaaac
tggaacaacat ctagatatcc aacagtgagg gtttaagcaac atgggtgcac tgtggataga
acgccaccca gccgcccgga gcagggactg tcattcaggg aggctaagga gagaggcttg
cttgggatat agaaagatat cctgacattg gccaggcatg gtggotcacg cctgtaatcc
tggcactttg ggaggacgaa gcgagtggat cactgaagtc caagagtttg agaccggcct
gcgagacatg gcaaaaccct gtctcaaaaa agaaagaatg atgtcctgac atgaaacagc
aggctacaaa accactgcat gctgtgatcc caattttgtg tttttctttc tatatatgga
ttaaaacaaa aatcctaaag ggaaatacgc caaatgttg acaatgactg tctccaggctc
aaaggagaga ggtgggattg tgggtgaact ttaatgtgta tgattgtctg tattttacag
aatttctgcc atgactgtgt attttgcatt acacatttta aaaataataa acactatttt
tagaat

```

wherein the codon $n_1n_2n_3$ and the codon $n_4n_5n_6$ are as defined in Figure 16A.

FIGURE 19

**Radioprotection of mice treated by FPAII-1
after irradiation at 15 Gy**




FIGURE 20

Low doses of FPΔII-11 mutein delay the death mice irradiated at 15 Gy




FIGURE 21

34/48

Parental (non-mutated) nucleotide sequence FPAIL-11 = SEQ ID NO:77 =

ATG GAC TAC AAG GAT GAC GAT GAC AAG GAA GGT CGT CGT GCA TCT
GTT GCA TCC CCA GAC CCT CGG GCC GAG CTG GAC AGC ACC GTG CTC
CTG ACC CGC TCT CTC CTG GCG GAC ACG CGG CAG CTG GCT GCA CAG
CTG AGG GAC AAA TTC CCA GCT GAC GGG GAC CAC AAC CTG GAT TCC
CTG CCC ACC CTG GCC ATG AGT GCG GGG GCA CTG GGA GCT CTA CAG
CTC CCA GGT GTG CTG ACA AGG CTG CGA GCG GAC CTA CTG TCC TAC
CTG CGG CAC GTG CAG TGG CTG CGC CGG GCA GGT GGC TCT TCC CTG
AAG ACC CTG GAG CCC GAG CTG GGC ACC CTG CAG GCC CGA CTG GAC
CGG CTG CTG CGC CGG CTG CAG CTC CTG ATG TCC CGC CTG GCC CTG
CCC CAG CCA CCC CCG GAC CCG CCG GCG CCC CCG CTG GCG CCC CCC
TCC TCA GCC TGG GGG GGC ATC AGG GCC GCC CAC GCC ATC CTG GGG
GGG CTG CAC CTG ACA CTT GAC TGG GCC GTG AGG GGA CTG CTG CTG
CTG AAG ACT CGG CTG TGA

Parental (non-mutated) amino acid sequence of FPAIL-11 = SEQ ID NO:78 =

MDYKDDDDKEGRRASVASPDPAELDSTVLLTRSLLADTRQLAAQLRDKFPA
DGDHNLDLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSS
LKTLEPELGTLQARLDRLRLRLQLLMSRLALPQPPDPPAPPLAPPSSAWGGIRA
AHAILGGLHLTLDWAVRGLLLLKTRL

FIGURE 22

35/48

Mutated nucleotide sequence of FPAIL-11 = SEQ ID NO:79 of the invention =

ATG GAC TAC AAG GAT GAC GAT GAC AAG GAA GGT CGT CGT GCA TCT
GTT GCA TCC CCA GAC CCT CGG GCC GAG CTG GAC AGC ACC GTG CTC
CTG ACC CGC TCT CTC CTG GCG GAC ACG CGG CAG CTG GCT GCA CAG
CTG AGG GAC AAA TTC CCA GCT GAC GGG GAC CAC AAC CTG GAT TCC
CTG CCC ACC CTG GCC ATG AGT GCG GGG GCA CTG GGA GCT CTA CAG
CTC CCA GGT GTG CTG ACA AGG CTG CGA GCG GAC CTA CTG TCC TAC
CTG CGG CAC GTG CAG TGG CTG CGC CGG GCA GGT GGC TCT TCC CTG
AAG ACC CTG GAG CCC GAG CTG GGC ACC CTG CAG GCC CGA CTG GAC
CGG CTG CTG CGC CGG CTG CAG CTC CTG ATG TCC CGC CTG GCC CTG
CCC CAG CCA CCC CCG GAC CCG CCG GCG CCC CCG CTG GCG CCC CCC
TCC TCA GCC TGG GGG GGC ATC AGG GCC GCC CAC GCC ATC CTG GGG
GGG CTG GTT CTG ACA CTT GCC TGG GCC GTG AGG GGA CTG CTG CTG
CTG AAG ACT CGG CTG TGA

Mutated amino acid sequence of FPAIL-11 = SEQ ID NO:80 of the invention =

MDYKDDDDKEGRRASVASPDPRAE~~L~~STVLLTRSL~~L~~ADTRQLAAQLRDKFPA
DGDHNLD~~S~~LPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSS
LKTLEPELGT~~L~~QARLDRLRLRLQLMSRLALPQPPDPPAPPLAPPSSAWGGIRA
AHAILGGL~~V~~LT~~L~~A~~A~~WAVRGLLLLKTRL

FIGURE 23

36/48

Primers used for inverse PCR mutagenesis of FPΔIL-11:

Muteins	Primers
H182/V	G422 pACACTTGACTGGGCCGTACGGGGAC (s) SEQ ID NO:81 G412 pCAGA <u>A</u> CCAGCCCCCCCAGGATGG (as) SEQ ID NO:82
D186/V	G410 pACACTTG <u>T</u> CTGGGCCGTACGGGGAC (s) SEQ ID NO:83 G421 pCAGGTGCAGCCCCCCCAGGATGG (as) SEQ ID NO:84
D186/A	G411 pACACTTG <u>C</u> CTGGGCCGTACGGGGAC (s) SEQ ID NO:85 G421 pCAGGTGCAGCCCCCCCAGGATGG (as) SEQ ID NO:86
H182/V- D186/V	G410 pACACTTG <u>T</u> CTGGGCCGTACGGGGAC (s) SEQ ID NO:87 G412 pCAGA <u>A</u> CCAGCCCCCCCAGGATGG (as) SEQ ID NO:88
H182/V- D186/A	G411 pACACTTG <u>C</u> CTGGGCCGTACGGGGAC (s) SEQ ID NO:89 G412 pCAGA <u>A</u> CCAGCCCCCCCAGGATGG (as) SEQ ID NO:90

FIGURE 24

37/48




Figure 25A




Figure 25B

38/48




Figure 26

39/48




Figure 27

40/48




Figure 28

41/48




Figure 29A




Figure 29B

42/48




Figure 30A






Figure 30B

43/48



44/48




Figure 32

45/48




Figure 33

46/48






Figure 34

47/48

**FIGURE 35**

48/48

**FIGURE 36**